

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> C07K 1/00, 7/54, 15/00 A61K 37/02, 39/00, 39/395 C12N 15/00, G01N 33/53	<b>A1</b>	<b>(11) International Publication Number:</b> WO 93/21206 <b>(43) International Publication Date:</b> 28 October 1993 (28.10.93)
<b>(21) International Application Number:</b> PCT/US93/03032 <b>(22) International Filing Date:</b> 31 March 1993 (31.03.93)  <b>(30) Priority data:</b> 07/866,040                      8 April 1992 (08.04.92)                      US 08/033,883                      19 March 1993 (19.03.93)                      US  <b>(71) Applicant:</b> THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10666 North Torrey Pines Road, La Jolla, CA 92037 (US).  <b>(72) Inventors:</b> SATTERTHWAIT, Arnold, C., Jr. ; 13681 Ru- ette le Park, Del Mar, CA 92014 (US). ARRHENIUS, Thomas ; 3909 San Augustine Way, San Diego, CA 92130 (US). CHIANG, Lin-Chang ; 13381 Jarman Place, San Diego, CA 92130 (US). CABEZA, Edelmina ; 9505 Genesee Avenue, #515, San Diego, CA 92121 (US).	<b>(74) Agents:</b> BOZICEVIC, Karl et al.; Morrison & Foerster, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).  <b>(81) Designated States:</b> AU, CA, FI, JP, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> SYNTHETIC, STABILIZED, THREE-DIMENSION POLYPEPTIDES  <b>(57) Abstract</b>  Methods for synthesizing three-dimensional stabilized peptides which mimic the three-dimensional configuration of the active site of a natural, biologically active protein are carried out by (1) noting the three-dimensional configuration of the active site of a known biologically active protein, (2) noting the amino acid sequence and the hydrogen bonds existing between amino acids which hydrogen bonds are capable of maintaining the three-dimensional configuration of the active site and (3) producing a synthetic three-dimensional peptide to mimic the structure of the active site. The synthetic peptide is synthesized so as to have the same or a similar amino acid sequence to the amino acid sequence of the active site of the biologically active polypeptide but with the stabilizing hydrogen bonds being replaced by a bridging divalent radical selected from the group consisting of $-(N)-C(CH_3)=N(H^+)-CH_2-(N)-$ ; $-(N)-C(CH_3)=N(H^+)-CH_2-CH_2-(N)-$ ; and $-(N)-N=CH-CH_2-CH_2-CH_2-(C)-$ .		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LI	Liechtenstein	SU	Soviet Union
CS	Czechoslovakia	LK	Sri Lanka	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	UA	Ukraine
DK	Denmark	MG	Madagascar	US	United States of America
ES	Spain	ML	Mali	VN	Viet Nam
FI	Finland	MN	Mongolia		

5     SYNTHETIC, STABILIZED, THREE-DIMENSION POLYPEPTIDESCross-References

          This application is a continuation-in-part of  
our earlier filed pending U.S. application Serial  
10   No. 07/866,040 first filed April 8, 1992 which  
application is a continuation-in-part of abandoned U.S.  
application Serial No. 07/607,645, filed October 29,  
1990, which application is a file-wrapper continuation of  
abandoned U.S. application Serial No. 07/179,160, filed  
15   April 8, 1988, which applications are incorporated herein  
by reference and to which applications we claim priority  
under 35 USC §120.

Technical Field

20           The invention relates generally to peptide  
chemistry and synthesis. In particular, it relates to  
the synthesis of peptides which mimic the three-  
dimensional conformation of all or a part of another  
peptide, polypeptide or protein by the replacement of one  
25   or more naturally occurring hydrogen bonds with a  
covalent bond to stabilize the molecules.

Background Art

          It has been well understood for decades that  
30   the three-dimensional conformation of a protein, as much  
as its primary amino acid sequence, is determinative of  
the effectiveness of the protein in its biological  
function. To some degree, of course, the three-  
dimensional conformation is an automatic consequence of  
35   the primary structure in the appropriate environment.

However, a large component in the factors accounting for the three-dimensional conformation is the ability of the components of the amide linkages to form interchain and mostly intrachain hydrogen bonds.

5           It is also known that sidechain amides participate in hydrogen bond linkages. The active regions of many proteins comprise relatively few amino acids. However, when the amino acid sequences of these active regions are isolated from the rest of the protein  
10 they generally show little or no activity. This is because short polypeptides (e.g., <20 aa) are unstable as regards their overall three dimensional structure and become disordered in H<sub>2</sub>O and/or under physiological conditions, i.e., they lose the three-dimensional  
15 structure which is provided when the short peptide is present in a longer protein.

Nature orders these active sequences by incorporating them into larger amino acid sequences, i.e., proteins where collective forces (e.g., intrachain  
20 hydrogen bonds) induce a three-dimensional structure. Accordingly, attempts have been made to stabilize the appropriate three-dimensional conformation of short peptides using linkages that are resistant to disruption. The three major approaches to such stabilization include  
25 cyclizing, forming disulfide bridges and using modified amino acids. These approaches are described briefly below.

First, peptides have been cyclized by linking N- and C-termini in an amide bond to provide similar  
30 shapes to those of the corresponding native proteins. C.M. Deber et al., Acct Chem Res (1976) 9:106; D.F. Veber et al., Nature (1981) 292:55. This approach is most effective with relatively small peptides, such as somatostatin. In the Deber paper, for example, a

bicyclic analog was shown to have a potency equal or greater than that of somatostatin.

In a second approach, disulfide bridges are formed in vitro to stabilize conformation. See, for example, A. Ravi et al., Tetrahedron (1984) 40:2577; R. Kishore et al., J Am Chem Soc (1985) 107:2986. These papers concern stabilization of  $\beta$ -turn conformations in a series of cyclic peptides, and  $\beta$ -sheets in cyclic peptides, respectively.

Finally, turn structures have been rigidified by utilizing modified amino acid sidechains in cyclization reactions. See, for example, R.M. Freidinger et al., Science (1980) 210:656; J.L. Krstenansky et al., Biochem Biophys Res Commun (1982) 109:1368; D.S. Kemp et al., Tetrahedron Lett (1982) 23:3759; D.S. Kemp et al., Tetrahedron Lett (1982) 23:3761; U. Nagai et al., Tetrahedron Lett (1985) 26:647; M. Feigel et al., J M Chem Soc (1986) 108:181; M. Kahn et al., Tetrahedron Lett (1986) 27:4841. For example, the Nagai paper describes the synthesis of a bicyclic amino acid which had an almost superimposable conformation on that of D-Ala-L-Pro of a type II  $\beta$ -turn in (D-Ala)-gramicidin. The Freidinger paper describes the synthesis of an LHRH analog using a lactam conformation constraint in the component amino acids.

T. Arrhenius et al., in a preview of the below-described work, presented at the UCLA/DuPont Protein Structure Meeting in April 1987 a poster which suggested the use of covalent substitutes for hydrogen bonding in helices,  $\beta$ -sheets, and turns, and described a hydrazone linkage substitute for an  $i \rightarrow i + 4$  hydrogen bond. This appears to be the first suggestion that hydrogen bonding can be covalently replaced by alternative covalent linkages. This and analogous substitutions would have the advantage of providing a reliable and

easily used method for assuring conformation in a wide variety of peptides. The construct was further described in Arrhenius et al., (1987) Protein Structure and Design (UCLA Symposium on Molecular and Cellular Biology)

5 69:453-465. The following describes that work as per our earlier patent applications and provides further disclosure on new methods of synthesis and structures of biologically active, stabilized structures.

#### 10 Summary of the Invention

The present invention involves the synthesis of a stabilized, three-dimensional peptide which mimics the three-dimensional structure of an active site of biologically active, naturally occurring protein. The  
15 procedures of the invention are carried out by determining (1) the amino acids and their sequence and (2) the approximate three-dimensional structural configuration of an active site of a naturally occurring biologically active protein. After determining the  
20 sequence and structural configuration, (3) one or more of the stabilizing hydrogen bonds are identified. After identifying a stabilizing hydrogen bond, (4) a synthetic peptide is produced with the same or only slightly modified amino acid sequence as the active site of the  
25 naturally occurring biologically active protein, wherein at least one of the stabilizing hydrogen bonds is replaced by the inclusion of a bridging divalent radical. In general, the hydrogen bond represented by  $H \cdots O$  is replaced by a covalent bond formed from a spatially  
30 equivalent covalent linkage selected from the group consisting of  $-(N)-C(CH_3)=N(H^+)-CH_2-(N)-$ ;  $-(N)-C(CH_3)=N(H^+)-CH_2-CH_2-(N)-$ ; and  $-(N)-N=CH-CH_2-CH_2-CH_2-(C)-$ , where the atoms in parentheses denote atoms corresponding to the amide and carbonyl peptide backbone atoms, i.e.,  
35 the latter link replaces  $-(N)-H \cdots O=C(R)-NH-CH_2-(C)$ . Two

classes of such bonds are found, as described below. Because the synthetic peptide can be made to mimic the three-dimensional structure of only a portion of a biologically active protein, i.e., the active site, it is possible to produce relatively small peptides which produce the same biological activity as their larger naturally occurring counterparts.

In addition to providing a method for creating synthetic peptides which mimic the three-dimensional structure of an active site of a naturally occurring biologically active protein, the present invention encompasses the synthetic peptides themselves. These peptides have the amino acid sequences similar to those of the corresponding naturally occurring polypeptides, but include at least one stabilizing covalent bond positioned strategically within the molecule in order to create a stable three-dimensional configuration which mimics the active site of the naturally occurring biologically active protein.

The stabilizing covalent bonds within these peptides may occur at locations other than those of the natural hydrogen bonds in order to further stabilize the synthetic molecule produced. The covalent "hydrogen bond mimic" of the invention is placed in a position so as to produce a stabilized form which mimics the essentials of the three-dimensional configuration of the naturally occurring, biologically active polypeptide. The synthetic peptides of the present invention generally include only a single replacement of a naturally occurring hydrogen bond in that this is generally sufficient to stabilize the three-dimensional, conformational structure of the molecule. The stabilization with respect to even a single stabilizing H-bond mimic may be sufficient to encourage additional three-dimensional stabilizing linkages in the molecule.



However, it may be necessary to substitute more than one hydrogen bond with a spatially equivalent covalent linkage especially where the structure being mimicked includes more than one basic type of configuration, e.g.,  
5 helical and loop configurations.

Those skilled in the art reading this disclosure will be able to determine the number of substitutions which will be necessary in order to stabilize the resulting synthetic molecule or such will  
10 be determined by experimentation carried out by following this disclosure. For example, it could be readily determined that only a single substitution is necessary in order to stabilize a helical structure. Once a single turn of the helix is established and its structural  
15 conformation locked into place, additional amino acid extensions on the helical chain will tend to form additional helical turns which are stabilized. Accordingly, the polypeptides which can be produced by Reaction Schemes 2, 3 and 5 can be directly useful in  
20 stabilizing helical structures and reverse turn configurations in the polypeptides derived therefrom.

A primary object of the present invention is to provide a method of synthesizing synthetic peptide molecules which have a three-dimensional structural  
25 configuration which mimics the three-dimensional structural configuration of the active site of a naturally occurring biologically active polypeptide.

Yet another object is to provide such a method wherein a hydrogen bond in a natural or synthetic amino  
30 acid sequence is replaced with a covalent mimic bond which is generally a double bond and is specifically a double bond between a carbon atom and a nitrogen group.

Another object is to provide such a method which uses solid phase synthesis methodology.  
35

Still another object is to provide such a method which can be adapted to manual or automated solid phase synthesis technology.

Another object of the present invention is to provide biologically active peptides which have a stabilized three-dimensional configuration which mimic the three-dimensional configuration of an active site of a naturally occurring biologically active polypeptide.

An advantage of the present invention is that long amino acid chains as well as relatively small amino acid chains can be stabilized in terms of their three-dimensional structure so as to maintain and/or enhance their biological activity.

Another advantage is that the methodology of the invention need only be used to produce a mimic structure as regards a sterically accessible bioactive region of a larger protein.

Yet another advantage is that proteins produced using the methodology of the invention are highly stable under diverse conditions including changes in temperature and solvent.

Still another advantage is that cyclic peptides have increased biological stability with respect to degradation by natural processes.

A feature of the present invention is that the methodology disclosed herein can be used in order to create a wide range of different synthetic biologically active polypeptides.

Another feature is that the method of the invention can replace hydrogen bonds with covalent bond mimics to obtain any desired three-dimensional structure.

Yet another feature is that the method can be used with any amino acid sequence and as such can be used with a natural sequence or an artificial sequence, i.e.,

a sequence which does not correspond to a natural protein or a portion thereof.

Another feature is that the method can be used with sequences which include modified amino acids.

5 Another feature of the invention is that the method is adaptable to solid phase synthesis methodologies.

These and other objects, advantages and features of the present invention will become apparent to those persons skilled in the art upon reading the details of the structure, synthesis and usage of the methods and stabilized peptides as more fully set forth below, reference being made to the structural formulae and included specific examples forming a part hereof.

15

#### Description of the Drawings

Figure 1 is a schematic view of commonly known protein configurations;

20 Figure 2 is a schematic view of a class 1 bridge, a biologically active EGF loop and a class 2 bridge;

Figure 3 is a schematic view of a predicted hydrogen bonding map for a consensus sequence for the loop region;

25 Figure 4 is a schematic view of five different class II mimics showing conformational restricted HIV peptides with the class II mimic referred to as HIV-2, HIV-3, HIV-4, HIV-5, and HIV-6;

30 Figure 5 is a schematic diagram showing the three-dimensional configuration of a protein and stabilized schematic views of a particular loop portion of the protein; and

35 Figure 6 is a flow diagram showing the synthesis for a stabilized loop of a shaped protein of the present invention.

### Detailed Description of Preferred Embodiments

Before the present method of synthesizing biologically active peptides which mimic the three-dimensional structure of the active site of natural protein and the synthetic peptides themselves are disclosed and described, it is to be understood that this invention is not limited to the particular methods and peptides described as such methods and peptides may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims.

It must be noted that as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a hydrogen bond" includes a plurality of such hydrogen bonds, reference to "the bridging divalent radical" includes a plurality of such bridging radicals and reference to "an amino acid" includes a plurality of amino acids of the same type, and so forth.

#### A. Definitions

As used herein, "protein" and "polypeptide" and "peptide" are used interchangeably to designate polymers or oligomers formed by amide linkages of amino acids. Although the terms are used interchangeably, regardless of the number of amino acid residues in the resulting structure an effort has been made to refer to the generally small molecules of the invention as peptides and the large naturally occurring molecules with active sites as proteins. These terms are also used to denote structures which are fundamentally polymeric amino acids, even though one or more of said "amino acids" may be

-10-

slightly modified to accommodate the linking moieties of the invention, or may be an amino acid analog. Unless otherwise noted, the amino acid residues are in the L configuration, but included within the invention are  
5 proteins which contain residues of the D configuration, as well as protein mixtures of enantiomeric forms of one or more amino acids. Additionally, one may include amino acids modified by substitution on the  $\alpha$ -carbon and/or amide nitrogen or extensions to replacements for the  
10 amide nitrogen. Suitable substitutions include, for example, oxy, halo, alkyl of 1-6 carbons, acyl of 1-6 carbons, benzyl, haloalkyl of 1-6 carbons, and the like.

The term "peptide analog" as used herein refers to compounds of the invention, wherein one or more  
15 natural amino acids are replaced by amino acyl moieties bearing one of the covalent linkers of the invention. A peptide analog has the same nominal amino acid sequence as the segment of the protein (i.e., the active site) it mimics, and differs from the active site by including a  
20 covalent bond in place of one or more of the stabilizing hydrogen bonds in the natural active site sequence or remote from the site that acts to stabilize it.

"Hydrogen bond" is used in the conventional sense to designate the relatively weak, noncovalent  
25 interaction between a hydrogen atom and another more negative atom. More specifically, the hydrogen is covalently bonded to a carbon or to an electronegative atom, such as nitrogen, oxygen, or chlorine, which hydrogen atom is also "hydrogen bonded" to an unshared  
30 electron pair of an electron donor atom, such as O, N, or Cl. The geometry of the hydrogen bond approaches linearity between the electron donating atom, the hydrogen, and the atom to which it is attached; however, it is understood that a reasonable deviation from  
35 linearity is included, and indeed, usually found.

By "corresponding native peptide" is meant the effective portion of the protein which the peptide of the invention is intended to replace. Thus, for example, the invention includes analogs of the active site of LHRH, somatostatin, growth hormones, enzymes such as the various serine proteases, antiviral proteins such as the interferons, lymphokines such as TNF, lymphotoxin, and the colony-stimulating factors, immunodominant epitopes found on the surface of infective pathogens, and so forth. The three-dimensional conformation of the active sites are generally assured by virtue of hydrogen bonding at various locations by formation of intrachain and interchain linkages. Replacement of these hydrogen bonds by the spatially equivalent covalent linkage prepared by the method of the invention results in a peptide having substantially the same activity as and thus "corresponding to" the active site of a native protein.

The terms "shaped peptide", "peptide mimics", "protein mimics", and "mimetopes" are all used interchangeably herein. The terms are intended to encompass any protein, polypeptide or protein analog which is produced in accordance with the claimed invention. Such shaped peptides include linked amino acids and/or analogs thereof and have one or more hydrogen bond replaced with a "spatially equivalent covalent linkage" as defined further below. The shaped peptides of the invention have been shaped in a 3-dimension configuration so as to have a targeted conformation designed so as to have the shaped peptide bind to a naturally occurring receptor site or bind to an antibody. The shaped peptide may be designed so as to cause the generation of antibodies which bind to the surfaces of pathogens which may be viral pathogens or bacterial pathogens.

By "spatially equivalent covalent linkage" is meant a substitute for the hydrogen bonding participants which linkage contains only covalent bonds, and which linkage holds the chains in essentially the same conformation as they would have been held by the hydrogen bonds. "Spatially equivalent" is also understood to accommodate minor deviations in exact spatial replication, so long as the resultant peptide has a biological activity. The activity may be greater than, less than, or preferably the same as the activity of the natural protein. The analog peptides of the invention may have antagonist activity, i.e., mimic the 3-D structure and thereby block the receptor site on the natural substrate and thereby hinder or eliminate the effect of natural proteins. For the purposes of the instant invention, "spatially equivalent covalent linkages" include  $-(N)-C(CH_3)=N(H^+)-CH_2-(N)-$ ;  $-(N)-C(CH_3)=N(H^+)-CH_2-CH_2-(N)-$ ; and  $-(N)-N=CH-CH_2-CH_2-CH_2-(C)-$ , where the atoms in parentheses denote atoms corresponding to the amide and carbonyl peptide backbone atoms, i.e., the latter link replaces  $-(N)-H\cdots O=C(R)-NH-CH_2-(C)$ . Even though the initial link is not strictly equivalent in length to the natural linkage it has been found to be useful in producing mimics.

#### B. General Description of the Invention

As indicated above, the invention includes methods of synthesizing peptides which mimic the three-dimensional structure of the active site of a naturally occurring protein and further includes the synthetic peptides, polypeptides and proteins produced by the methodology of this invention. The invention is carried out by first identifying a natural protein and a sterically accessible biologically active site of such a protein which provides for biological activity. After

the protein fragment is identified, the amino acid sequence of a natural protein of interest is identified. Based on the sequence a structural prediction is made. To the extent possible, the three-dimensional structure is verified (e.g., forming a crystal and making and analyzing an x-ray diffraction pattern) and hydrogen bonds which stabilize that three-dimensional structure are determined. Methods of predicting and verifying the three-dimensional structure of a protein or portion thereof are described further below. Next, a peptide is synthesized using conventional synthesis technology (preferably automated solid phase technology) to obtain a peptide having an amino acid sequence that will lead to the three-dimensional conformation of the active site being mimicked. In general, the primary structure of the amino acid sequence will be identical or substantially identical to that of the corresponding protein. Then the novel chemistry of the present invention is used to include a covalent bond in place of a hydrogen bond to thereby lock the three-dimensional structure of the peptide in place. This is done by reacting a bridging, divalent radical with the amino acids in the peptide which are held in place by stabilizing hydrogen bonds. Accordingly, the invention can be used to mimic the three-dimensional structure of a wide range of different biologically active naturally occurring proteins. In addition to mimicking (to the extent possible) the three-dimensional structure of natural proteins, it is possible to vary the three-dimensional structure slightly in order to obtain an enhanced, a reduced, or a blocking effect as compared with the effect obtained by the natural protein.



C. Determining the Three-Dimensional Structure of a Protein or Active Site Thereof

The present invention is not directly involved in recovering and/or analyzing proteins. More specifically, the present invention does not disclose a novel method of isolating, sequencing and/or further characterizing protein such as determining the biological activity, active sites and/or three-dimensional structures of a given protein. Procedures for doing such are known to those skilled in the art and new procedures will no doubt be developed in the future which procedures can then be used with the present invention.

Having made the above statement, it is clear that the practice of the present invention requires that one begin with some information on the protein of interest. The information can be as general as the DNA sequence which encodes the protein of interest to knowledge of an amino acid sequence and three-dimensional structure of the active site of a protein. In general, the more information available publicly on a given protein, the easier it is to adapt the methodology of the present invention to work with that protein. However, when little information is available, known procedures can be used to extract sufficient amounts of information so that the procedure of the present invention can be used.

When only the DNA sequence is known, the genetic code can be used to determine the amino acid sequence. Once the amino acid sequence is known, there are a number of computer programs available which can generate a probable three-dimensional structure. (See J.F. Gibrat et al. (1987), J. Mol. Biol. 198:425-443). The reliability of such programs is continually improving and their reliability is very high when used to determine the three-dimensional structure of certain sequences

which tend toward certain three-dimensional configurations. Such programs can be applied to an entire sequence or to a sterically accessible region thought to be the active site.


5

### Common Configurations in Proteins

It is highly probable that any given protein will include a sterically accessible bioactive region which includes one of the following configurations shown in figure 1.

Figure 1 shows the hydrogen-bonding patterns of common secondary structures. The symbols shown in figure 1 are defined as follows:  $\alpha$ -carbon ( $\bullet$ ), carboxyl terminus ( $\rightarrow$ );  $C_\alpha$ -CO-NH- $C_\alpha$ -CO ( $\bullet\cdots\bullet\rightarrow$ ); amide-amide hydrogen bond ( $\cdots$ ).

Any of the above configurations can be stabilized by the use of the bridging divalent radical of the invention whereby stabilizing hydrogen bonds are replaced with the covalently bound linking groups of the invention. For example, the  $\beta$ -hairpin loop can be stabilized to form the following specific stabilized structures:



2:2  $\beta$ -Hairpin Loop

Loop with Class 1 MimiC

35

In another example, the alpha helix can also be stabilized. The circled letters indicate alpha carbons and side chains for amino acids according to the one letter amino acid code.

5

10



15

20

25

30

35

 $\alpha$ -helix $\alpha$ -helix with  
Class 2 mimic

In addition to computer programs, one can use X-ray crystallography techniques as well as NMR spectroscopy to determine the three-dimensional structure of purified proteins and portions thereof. Further, the three-dimensional structure and activity of some proteins is known and all that is required is the retrieval of such information followed by the application of the methodology of the present invention. After the stabilized structures of the invention are made, the same techniques and procedures used to determine the three-dimensional structure of the protein can be used to confirm that the stabilized peptides mimic the structure they were intended to mimic.

It is of course possible to apply a variety of techniques to obtain as much information as possible about the three-dimensional structure of a protein of interest. Regardless of the techniques used, amino acid sequence information must be obtained and information on the structural conformation of a sterically accessible region which is putatively the active site must be sufficient such that a determination can be made as to the location of a hydrogen bond which stabilizes the three-dimensional configuration of that active site. When such information is obtained or is already available, the methodology of the present invention can be applied in order to produce a peptide which includes a covalent bond that mimics the hydrogen bond of the natural protein and thereby stabilizes the three-dimensional structure of the peptide in substantially the same conformation as the active site of the protein.


#### D. Synthesis of Peptide Analogs

The peptides are produced by first attaching the amino acids to each other using procedures known to those skilled in the art, i.e., conventional peptide

synthesis including automated solid phase synthesis. The result of such conventional procedures will be a peptide with the desired amino acid sequence but with no particular stable three-dimensional structure. In particular, the three-dimensional conformation will change continually when the peptide is in water or a physiological environment due to the weakness of the stabilizing hydrogen bonds. The essence of the present invention is the modification of such a structurally unstable peptide so as to stabilize the three-dimensional structure in water and/or an in vivo environment.


The stabilization is carried out by including a stabilizing covalent bond. This can be done, for example, by replacing a hydrogen bond existing between two amino acids in the natural protein with a covalent bond between corresponding (or closely positioned (e.g., 2-2000 amino acids)) amino acids or modified forms thereof in the synthetic peptide. The covalent bond permanently stabilizes the configuration of the two attached amino acids and thereby provides sufficient structural orientation so that the other amino acids in the peptide will align in their natural three-dimensional conformation (using hydrogen bonds) which matches the natural three-dimensional conformation of the active site of the natural protein. Thus, adequate stabilization of the mimic may be obtained by substitution of only one hydrogen bond by a covalent linkage. Furthermore, this stabilization may occur in a generic portion of the molecule to which a desired amino acid sequence may be coupled, the generic stabilized portion generating the correct three-dimensional structure in the target peptide.

The amino acids in natural proteins are connected by hydrogen bonds which appear as follows:




10 The hydrogen bond must be replaced by a covalent double bond in order to stabilize the three-dimensional conformation of the molecule. The hydrogen bond can be replaced by a variety of molecular configurations which, when in place, tend to mimic the hydrogen bond as it exists in the whole natural protein.

15 With reference to the above natural double bond, it is pointed out that the hydrogen and oxygen atoms forming the double bond cannot be merely replaced by two different atoms without modifying the manner in which those are atoms attached to their respective nitrogen and carbon atoms, i.e., the hydrogen bond configuration is not changed to




30 where each X is independently any atom of appropriate electron configuration. However, the natural hydrogen bond configuration can be changed to

35




wherein  $X_1$ - $X_6$  are each independently an atom or molecular group of atoms with the required electron configuration allowing for the formation of the bonds shown.


The natural configuration can also be changed to



Yet another configuration is:




wherein  $X_3$ - $X_7$  are defined as above and  $X_3$  and  $X_4$  are preferably defined so to provide




10

or alternatively



20

Further,  $X_5$  and  $X_6$  are preferably defined in structure (5) to provide



30

#### E. Application to EGF Hormone

The methodology of the invention which includes hydrogen bond mimics may be used to make peptides which will find wide applications as pharmaceutical drugs, hormone replacements, diagnostic reagents, synthetic vaccines, complexing reagents and catalysts. An

35



illustrative example of such is an active fragment of epidermal growth factor (EGF), comprising amino acids 20-31 (A. Komoriya et al., Proc Nat Acad Sci USA (1984) 81:1351-55). Figure 2 shows the structure and binding involved in (1) a Class I bridge; (2) a biologically active EGF Loop; and (3) a Class 2 bridge.

The peptide's activity is about  $10^{-4}$  that of the parent molecule. The decreased activity was attributed to a loss, i.e., change in structure. In the intact protein, residues 20-23 and 28-31 form anti-parallel  $\beta$ -sheets, joined by residues 24-27 in a reverse turn (G.T. Montellione et al., Proc Nat Acad Sci USA, 83:8594-98 (1986)). Either class of mimics of the present invention may be used to stabilize the conformation of the peptide fragment. For Example, a class 1 aminoethaneamidinium bridge (Scheme 3) might be used to stabilize the reverse turn structure between residues 24 and 27 and the M21(N-H):T30(C=O) hydrogen bond while a class 2 bridge might be used to stabilize the M21(C=O):T30(NH) hydrogen bond as shown above. Similarly, class 1 and class 2 bridges might be used to stabilize the hydrogen bonds which form between V19 and N32. Thus, by utilizing both bridges one may systematically replace each of the putative hydrogen bonds in the EGF peptide to give a series of EGF peptides derivatives of increasing size.

Covalent mimics may also be employed to conformationally restrict synthetic peptide vaccines. Peptides shaped to correspond to the three-dimensional surface of proteins should induce antibodies with binding pockets which closely complement the native protein surfaces. Three-dimensional complementarity between the antibody and protein surfaces should lead to tighter binding interactions and improve the affinity. The overall immune response to conformationally restricted

peptides should show greater efficiency than the unrestricted peptides of the prior art.

In another example illustrating a potential use for this methodology, an EGF-like protein isolated from human malaria has been proposed as a candidate vaccine (D.C. Kaslow et al. (1988) Nature 333:74-76). Peptide sequences homologous to the EGF-like sequences from the malaria protein could be conformationally restricted in the same manner using Class I and Class II mimics for use as a synthetic vaccine.

#### F. Survey of Conformations and Hydrogen Bond Types

The results of a reasonable number of X-ray crystallographic studies of protein conformations have permitted the assessment of shapes and the assignment of the nature of hydrogen bonds securing these conformations at a molecular level. Certain conventions have been followed in designating the types of hydrogen bonds denoted. In general, the participants are designated in terms of a reference residue,  $i$ , and an additional residue ( $i + \#$ ) which is that residue which is located the designated number ( $\#$ ) of residues further downstream (starting from the N-terminus of the chain). The hydrogen bond itself is designated by an arrow which points in the direction of hydrogen donation--i.e., the arrow points from the residue donating the hydrogen toward the residue bearing the electrons that accept them. Thus, for example, an ( $i + 4 \rightarrow i$ ) hydrogen bond is the donation of hydrogen from the nitrogen in the  $i + 4$  residue to the oxygen of the carbonyl group on the  $i$  residue 4 amino acids downstream. A hydrogen bond between these participants results in an  $\alpha$ -helix.


Table 1 shows representative examples of the types of hydrogen bonds which are recognized to form commonly encountered conformational characteristics of

single-chain and interchain-linked proteins. Some of these conformations are more frequently encountered than others. Approximately 80-90% of all globular proteins are found in the form of either  $\alpha$ -helices,  $\beta$ -sheets, or  $\beta$ -turns, each of which is shown above as are other types of turns and helices which are less common. In Table 1, the type of hydrogen bond is shown along with the ring size--i.e., the number of atoms forming the resulting ring (including the electron-donating atom and the hydrogen). A detailed description of these structures is provided by J.S. Richardson, *Advances in Protein Chemistry*, 34:167 (1981); Dickerson RE, Geis I. (1980) in "The Structure and Action of Proteins." Benjamin/Cummings Publishing Co; Sibanda LS et al, *J. Mol. Biol.* 206:759-777 (1989); Wilmot CM and Thornton JM, *J. Mol. Biol.* 203:221-232 (1988). The resulting structures are shown as the type of secondary or tertiary structure obtained as a consequence of the hydrogen bond type given.

Table 1

	Hydrogen Bond	Ring Size	Secondary or Tertiary Structure
	$i + 2 \text{ ---} \rightarrow i$	7	$2_7$ ribbon
5	$i + 3 \text{ ---} \rightarrow i + 1$	10	$3_{10}$ helix; reverse turns of the Type I, I', II, II', III, IV, IVa, IVb etc.
	$i + 4 \text{ ---} \rightarrow i$	13	alpha helix; 3:3 loop (rare, various)
10	$i + 4 + n \text{ ---} \rightarrow i$	$13+3n$	$n=1 - 20$ ; hairpin loops
	$i \text{ ---} \rightarrow i + 3$	14	2:2 loop (defined types); 2:4 loop (unusual, various)
	$i \text{ ---} \rightarrow i + 3 + n$	$14+3n$	$n = 1 - 20$ ; hairpin loops
15	$i + 5 \text{ ---} \rightarrow i$	16	$\pi$ helix (hypothetical structure, never observed); 4:4 loop (defined and various)
	$i \text{ ---} \rightarrow i + 4$	17	3:5 loop (defined and various)
20	$i \text{ ---} \rightarrow i + 5$	20	4:6 loop (many conformations)

In addition to these intrachain linkages, antiparallel and parallel  $\beta$ -sheet hydrogen bonding can also be substituted by the covalent linkers of the invention. The schematics of these interchain bonds are as follows:




In addition to the foregoing, since the side chains of glutamine, aspartic acid, serine, glutamic acid, cysteine, threonine, lysine, arginine, histidine, tryptophan or tyrosine donate or accept hydrogen atoms, sidechain-sidechain and sidechain-backbone hydrogen bonds can be formed, for example, between two asparagine residues, asparagine and glutamine, or glutamine and glutamine, or between these amide sidechains and the backbone residues.

The covalent moieties which mimic the hydrogen bonds can be used to replace any of the foregoing linkages to maintain the desired secondary or tertiary structure.

#### G. Types of Hydrogen Bond Mimics

Two major classes of mimics have been found which are successful in replicating the geometry of the hydrogen bonds of native proteins. These are shown in comparison to the "Normal" or typical hydrogen bonds below as class 1 and class 2.



Class 1 utilizes an alkylamidine linkage in place of the hydrogen bond. The hydrogen of the hydrogen bond ordinarily attached to the  $\alpha$ -amino group of the amino acid is replaced by  $-CR=$ , wherein R is H or alkyl (1-6C) or an extended acid  $-(CH_2)_n-CO_2H$  where  $n=1-6$  and

th electron pair donating oxygen of the carboxyl group of the  $i + \#$  amino acid is replaced by  $\text{-NH-}$ .

Class 2 of covalent linkers are hydrazone-hydrocarbon links. In this embodiment, the hydrogen of the  $\alpha$ -amino of the  $i + \#$  amino acid is replaced by a  $\text{-N=}$ , which is, in turn, covalently linked by a double bond to a  $\text{-CH=}$  residue which takes the place of the carboxyl oxygen of the  $i$  residue.

Either of the foregoing classes of mimics can be used in the hydrogen bond configurations shown in Table 1 and in the interchain bonds. In the preferred embodiments the Class I mimic substitutes in the  $i \rightarrow i + n$  sense, while the Class II mimic substitutes in the  $i + n \rightarrow i$  sense (Table 1). However, new syntheses can be written for substituting Class I and II mimics in the alternative fashion. Accordingly, the present invention makes it possible to substitute the  $\text{-CR-NH(+)-}$  and  $\text{-N=CH-}$  hydrogen bond mimics, or any double bond substitution for the hydrogen bond in either sense either backbone to backbone or side chain to backbone or side chain to side chain.

The synthesis of these mimics in the context of peptide chains is illustrated below. As also noted, modifications in the peptide chain in the immediate vicinity of the hydrogen bond mimics may also be included. When synthesized, the mimics may be chain-extended to form the remainder of the peptides using standard protein synthesis techniques.


One aspect of the invention is a stabilized polypeptide, which comprises a sequence of at least two amino acids or amino acid equivalents linked by peptide bonds, wherein at least one hydrogen bond of the formula  $(\text{C})=\text{O} \cdots \text{H}-(\text{N})$  is replaced by a bridging covalent bond of the form  $\text{-(N)-CR-NH- (C)-}$  or  $\text{-(N)-N=CH- (C)-}$ . The stabilized peptides of the invention preferably include

2-2,000 amino acids and more preferably 2-30 amino acids. The method of the invention is most effective in low molecular weight peptides as stabilization by ordinary conformational folding and hydrogen bonding is enhanced in large proteins.

Preferred embodiments of the invention include those wherein the covalent hydrogen bond mimics of the invention form interchain links between atoms forming the backbone of the polypeptide. Additional preferred embodiments include those wherein side chain elements form intrachain linkages. A preferred subclass comprises the polypeptide where the amino acid chain and the hydrogen bond mimics are selected to form rings having 7, 10, 13, 13+3n, 14, 14+3n, 16, 17 or 20 atoms where n=1-20 as indicated in Table 1. However, these are only examples and rings of other sizes from 7-6,000 are not excluded.

One preferred class of compounds of the invention comprises the compounds of the formula

20




25

wherein (aa)<sub>n</sub> is an amino acid sequence of 1 - 2000 (i.e., aa is an amino acid and n is an integer from 1 to 2,000). R<sup>4</sup> is a hydrogen, or alkyl moiety containing 1-6 carbon atoms, or an acid -(CH<sub>2</sub>)<sub>n</sub>-(O<sub>2</sub>H<sub>3</sub>) n=1-6 which can be extended with an amino acid sequence of 1-2000 amino acids, or an amino acid sequence of 1 - 2000 or a -NH-CHR-COOH or a -CH-CHR-COOH where R is the side chain of a natural or unnatural amino acid. m is an integer from 0-

35

6.  $R^1$  is hydrogen or alkyl (1-6) or an acid  $-(CH_2)_n-CO_2H$ ,  $n = 1 - 6$  which can be extended by an amino acid sequence of 1 - 2000 amino acids.  $R^2$  is H or alkyl (1-6C) or an amino acid sequence of 1 - 2000 amino acids and
- 5  $R^3$  is the side chain of a natural or unnatural amino acid. A presently preferred compound is that wherein  $(aa)_n$  is Ala-Ala,  $R^4$  is hydrogen,  $m$  is 0, both  $R^1$  and  $R^2$  are methyl and  $R^3$  is the side chain of glycine, i.e., H. Another presently preferred compound is the compound
- 10 wherein  $(aa)_n$  is Ala-Ala,  $R^4$  is hydrogen,  $n$  is 1, both  $R^1$  and  $R^2$  are methyl and  $R^3$  is H. Another presently preferred compound is the compound wherein  $(aa)_n$  is Glu-Ser-Leu,  $R^4$  is hydrogen,  $n$  is 1, both  $R^1$  and  $R^2$  are methyl and  $R^3$  is H.
- 15 Another presently preferred class of compounds of the invention comprises the compounds of the formula:




- 25 wherein  $R^5$  is alkoxy of 1-6 carbons, phenoxy, naphthyloxy, benzoxy,  $-NH_2$  or an amino acid sequence of 1-2,000 amino acids,  $(aa)_n$  is an amino acid sequence of 1-2,000 amino acids,  $X$  is a nonentity,  $-CH_2-$ ,  $-NH-$ ,  $-CH-$  or  $-NH$ , with the double bonds to  $CHR^6$   $n$  is an integer
- 30 from 0-5.  $R^6$  is a nonentity, H,  $-NH_2$  with or without an amino acid extension of 1-2000 amino acids, alkyl (1-6C) or an alkyl amine  $(CH_2)_n-NH_2$  where  $n=1-6$  with or without an amino acid extension of 1 - 2000 amino acids. A
- 35 presently preferred compound of the invention is that wherein  $R^5$  is Et,  $(aa)_n$  is Leu-Ala,  $X$  is  $-CH_2-$ ,  $n$  is 1,



and  $R^6$  is H. Another presently preferred compound is the compound wherein  $R^6$  is  $NH_2$ ,  $(aa)_n$  is Ile-Glu-Ser-Leu-Asp-Ser-Tyr, X is  $-CH_2-$ , m is 1 and  $R^5$  is H. Another presently preferred compound is the compound wherein  $R^5$  is  $NH_2$ ,  $(aa)_n$  is Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys, X is  $-CH_2-$ , n is 1 and  $R^5$  is H.

#### Synthesis of Class 1 Mimics


The basic reaction for formation of class 1 linkers can be conducted using a thioamide selectively activated with methyl iodide to yield a thioimidate which subsequently reacts with an unprotected primary amine according to the reaction:




In the foregoing reaction and throughout this disclosure, "--" indicates extension of the peptide chain.

Reaction scheme 1 shows the application of this reaction to the formation of the desired linkage in the context of the intrachain mimic:

Scheme 1(a)




Reaction Scheme 1(b)


20 Reaction scheme 1(b) is formally identical to Scheme 1(a) and encompasses a preferred class of compounds of the invention (5).

25 For adaptation to peptide synthesis, the  $\text{R}_4$ -bearing residue is linked to an amino acid or a sequence of amino acids and a thiolamide analogue to yield an intermediate that is finally cyclized. For example, an  $i \longrightarrow i + 3$  hydrogen bond is replaced in a 2:2 loop by placing a dipeptide intermediate to the residue containing the aminoethyl substituent and the residue containing the thioamide, according to reaction scheme 1(c).

35

Reaction Scheme 1(c)

-34-

Reaction Scheme 1(c) con't

SUBSTITUTE SHEET

Th basic reaction is the displacement of a methylthio substituent with a primary amine which is itself a alkylamino substituent to an amide nitrogen of the same or different chain in the peptide. According to the schematic used to illustrate the invention herein, the oxygen of the carbonyl which would have been the electron donor atom in the hydrogen bond is replaced by an ~~CNH~~. On the other hand the former carbonyl carbon of the thiolamide which is converted to the central carbon of an amidinium group replaces the hydrogen which would have accepted the electron donation. As shown in reaction scheme 1(a) and 1(b), the resulting ~~CR-CNH~~ double bond replaces the donated electrons and the recipient hydrogen, i.e., the hydrogen bond.


The detailed chemistry for introducing a class 1 mimic into a peptide chain was developed in the context of a 2:2 loop and is depicted in Scheme 1(c). The reactions for each step are set forth in the Examples below. The structure of the final product was verified as folding the inserted peptide into a Type 1 reverse turn by both X-ray crystallography and in solutions of dimethyl sulfoxide or water using both one-dimensional and two-dimensional NMR spectroscopy. It has been established by X-ray crystallography that approximately 10% of the amino acids in globular proteins fold into the Type 1 reverse turn structure. C.W. Wilmot and J.M. Thornton, J. Mol. Biol. 203:221 (1988) Reverse turns provide a means for the polypeptide chain to fold back on itself allowing for a globular form. Consequently, they are located almost exclusively on protein surfaces where biological activity occurs. The reactions for each step are set forth in the Examples below.

In the Schemes below, the following abbreviations are used: Cbz = carbobenzoxy, Me = methyl, Et = ethyl, Bu = butyl, Ac = acetyl ( $\text{CH}_3\text{C=O}$ ), DPPA =


diphenylphosphoryl-azide, TEA = triethylamine, EDC = N-ethyl-N'-3-dimethylaminopropylcarbodiimide hydrochloride, HOBT = 1-hydroxybenzotriazole, DMF = dimethyl formamide, TFA = trifluoroacetic acid, Ms = mesyl (methane sulfonyl), Bz = benzyl, Boc = t-butoxycarbonyl, THF = tetrahydrofuran, Im = imidazolyl, and DMAP = N,N-dimethylaminopyridine. All starting materials are either available from commercial sources, and/or are described in the literature.

### Scheme 2


#### Step 1:




#### Step 2:




#### Step 3:










#### Step 4:





#### Step 5:







Step 6:5 Step 7:Step 8:Step 9:Step 10:Step 11:Step 12:




Step 13:Step 14:

Using similar chemistry, an aminoethane amidinium link (Class I link) was introduced in the context of replacing an i+i-->i + 3 hydrogen bond in a 2:2 loop in Scheme 1c and Scheme 3 which follows. Each step of the reaction scheme is set forth in detail in the examples below.


Scheme 3Step 1:Step 2:Step 3:Step 4:

Step 5:


5

Step 6:


10

Step 7:Step 8:


15

Step 9:


20

Step 10:


25

Step 11:




30

Step 12:

35



-40-

Step 13:Step 14:Step 15:

The structures of the final products from Scheme 2 and 3 were verified as folding the peptide into a Type 1 reverse turn in both dimethyl sulfoxide and water using one and two-dimensional nmr spectroscopy. 2D nmr experiments included COSY and ROESY experiments. The predicted temperature coefficients, J<sub>an</sub> coupling constants and nuclear Overhauser enhancements for a Type 1 reverse turn (Wuthrich, K. In: NMR of Proteins and Nucleic Acids, J. Wiley & Sons, New York, p. 166 (1988)) are all observed for the final products of Scheme 2 and 3. An X-ray crystal structure for the product of Scheme 3 is also in agreement with the Type 1 reverse turn conformation. The reactions outlined in Scheme 3 have been used to synthesize six different compounds which incorporate different amino acids and display the same basic Type 1 reverse turn conformation (L. Chiang et al. (1990) In: Peptides 1990, Proceedings of the 21st European Peptide Symposium. Giralt E.,


-41-

Andreu D (eds). ESCOM Science, Leiden, the Netherlands, 1991, p 465)

It has been established by X-ray crystallography that approximately 10% of the amino acids in globular proteins fold into the Type 1 reverse turn structure and that the structure is located almost exclusively on the protein surface (P.Y. Chou and G.D. Fasman, J. Mol. Biol. (1977) 115:135; C.M. Wilmot and J.M. Thornton, J. Mol. Biol. (1988) 203:221) where biological reactions often occur (G.D. Rose et al., Adv. in Prot. Chem. (1985) 37:1).

#### Synthesis of Class 2 Mimics

The class 2 mimics are generated by reaction of a hydrazine derivative with an acetal or ketal according to the general reaction:



In the context of intrachain bonding, the reaction is as shown in Scheme 4.

In the case of a class 2 mimic, the hydrogen bond is replaced by the carbon-nitrogen double bond (C=N) of an N-acyl hydrazone. This hydrazone is formed by a condensation reaction between an N-amido peptide and a peptide fragment bearing an aldehyde moiety, masked in the form of an acetal. Scheme 4 outlines the synthesis of class 2-containing peptides. The synthesis is a convergent one. The two fragments 31 and 37 are

**SUBSTITUTE SHEET**

synthesized in parallel, then combined in a peptide condensation reaction. In the final step, the hydrogen bond mimic is formed by a cyclo-condensation reaction between the hydrazide and the acetal functional groups.

- 5 Three types of 31 fragment (31a, 31b, 31c) are illustrated.

10


15

20

25


30

35




Reaction Scheme 4(a)

Reaction scheme 4(a) includes the reactions steps shown above in reaction scheme 1(a) applied to a preferred class of compounds.



Reaction Scheme 4(b)

Yet another example of such a reaction is shown below.



15


The synthesis of one particular peptide containing a class 2 hydrogen bond mimic is shown in Scheme 5. The experimental details are set forth in the examples below. All syntheses were characterized by NMR spectroscopy and high resolution mass spectroscopy. Detailed conformational analysis of these peptides were carried out using a combination of one and two-dimensional NMR techniques, including Difference Nuclear Overhauser Effect spectroscopy, COSY spectroscopy, and coupling constant analysis. The product produced is helical in character.

20

25

Scheme 5








30

Step 1:

35




-46-

Step 2:5 Step 3:10 Step 4:15 Step 5:20 Step 6:25 Step 7:30 Step 8:

35

Step 9:



Detailed conformational analysis of the final product alone and appended to short amino acid chains (6-11 amino acids) in trifluoroethanol and water was carried out using 1D and 2D nmr spectroscopy. Preliminary conformational studies have been reported (T. Arrhenius and A.C. Satterthwait In: Peptides: Chemistry, Structure and Biology. Proceedings of the Eleventh American Peptide Symposium. Riview J.E., Marshall, G.R. (eds) ESCOM Leiden, the Netherlands, p. 870 (1990); L.-C Chiang et al. In: Peptides 1990. Proceedings of the 21st European Peptide Symposium. Giralt E., Andreu D. (eds) ESCOM Science, Leiden, the Netherlands, 1991, p. 465). These studies utilize 1D and 2D NMR spectroscopy, including COSY, double quantum filter COSY, TOCSY experiments and selective deuterium labeling for the assignment of signals, measurements of Jan coupling constants, and the determination of deuterium exchange rates and temperature coefficients. Nuclear Overhauser enhancements (both short and midrange) were identified in 2D ROESY experiments. These studies are in complete agreement with prediction (K. Wuthrich et al., J. Mol. biol. 180:715 (1984)) and fully establish that the Class 2 mimic when substituted for an  $(i + 4) - i$  hydrogen bond stabilizes peptides in the alpha helical

conformation in trifluoroethanol and water at ambient and physiological temperatures.

Thus, both classes of mimic can be used to stabilize a conformation ordinarily stabilized by hydrogen bonding in the context of a growing peptide chain, or can be formed even more simply between parallel or antiparallel chains in sheets. This evidences the broad scope of utility of these mimics, which can be put into the context of any desired peptide.

#### Examples

The following examples are presented as a further illustration for the practitioner of ordinary skill in the art, and are not intended to limit the scope of the invention in any manner. The following examples demonstrate solution-phase synthesis; however, other methods (e.g., solid phase synthesis) are also considered within the scope of this invention.

#### Example 1

(Scheme 2, Step 1)

N-benzyloxycarbonyl-alanine N-hydroxy-succinimide ester (1) was synthesized according to the procedure described by G.W. Anderson et al., J Am Chem Soc (1964) 86:1839.

Briefly, equal moles of N-Cbz-ala, N-hydroxy-succinimide, and dicyclohexylcarbodiimide were added in THF in an ice-water bath with stirring. The mixture was kept in a cool room (0°C) overnight. The dicyclohexylurea precipitate was removed by filtration, and the solvent evaporated in vacuo. The residue was crystallized from isopropanol to yield 1.

Example 2

(Scheme 2, Step 2)

Cbz-alanine N-hydroxysuccinimide ester (1, 20 mM) was dissolved in absolute ethanol (EtOH, 50 ml), and the solution added to a solution of glycine (20 mM) and NaHCO<sub>3</sub> (40 mM) in water (50 ml). The mixture was stirred at room temperature overnight, concentrated to a small volume with a rotary vacuum evaporator, and acidified to pH 2 with concentrated HCl. The product was crystallized by cooling the mixture in an ice-bath, and recrystallized from ethyl acetate-hexane to provide Cbz-Ala-Gly (2).

Example 3

(Scheme 2, Step 3)

Following the procedure of T. Shioiri et al., J Am Chem Soc (1972) 94:17, equal moles of Cbz-Ala-Gly (2), diphenylphosphorylazide (DPPA), and triethylamine (TEA) were dissolved in t-butanol. The mixture was refluxed overnight. After evaporation of the solvent, the neutral fraction in ethyl acetate obtained after aqueous acid and alkali work ups was purified by silica gel column chromatography or crystallization from ethyl acetate-hexane, to yield Cbz-Ala-CONHCH<sub>2</sub>NH-Boc (3).

Example 4

(Scheme 2, Step 4)

To a solution of 3 (10 mM) in EtOH in a round bottom flask was added a small amount of Pd/C catalyst. A balloon filled with hydrogen was attached to the flask. After repeated degassing, the flask was filled with hydrogen and the mixture vigorously stirred for 30 min and filtered through celite to provide NH<sub>2</sub>-Ala-CONHCH<sub>2</sub>NH-Boc (4).

Example 5

(Scheme 2, Step 5)

5 Cbz-alanine N-succinimide ester (1, 10 mM) was added to the 4 product solution from Example 4. The mixture was agitated overnight and concentrated to a small volume with a rotary vacuum evaporator. The product was crystallized from the mixture with addition of distilled water to yield Cbz-Ala-Ala-CONHCH<sub>2</sub>NH-Boc (5).

10

Example 6

(Scheme 2, Step 6)

Compound 5 was deprotected by catalytic hydrogenolysis using the procedure described in Example 4 above, to provide NH<sub>2</sub>-Ala-Ala-CONHCH<sub>2</sub>NH-Boc (6).

15

Example 7

(Scheme 2, Step 7)

20 Sarcosine (250 mM) and p-toluenesulfonic acid (TsOH, 255 mM) were added to a mixture of benzyl alcohol (100 ml) and toluene (50 ml). The mixture was heated to reflux, and the water formed by the reaction trapped in a Dean Stark receiver. When no more water appeared in the distillate, the mixture was cooled to room temperature, added to ether, and cooled in an ice-water bath for two  
25 hr. The crystalline product was collected on a filter and recrystallized from CH<sub>2</sub>Cl<sub>2</sub>-Et<sub>2</sub>O to yield MeNHCH<sub>2</sub>COOCH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>) TsOH (7).

Example 8

30

(Scheme 2, Step 8)

Acetic anhydride (AcOAc, 10 mM) was slowly added to a solution of 7 (10 mM) and TEA (20 mM) in THF with stirring. The mixture was left to stand at room temperature for 2 hr after the addition of acetic  
35 anhydride was completed. After the solvent was removed

by vacuum evaporation the residue was redissolved in ethyl acetate and washed with citric acid (1 M),  $\text{NaHCO}_3$  (0.5 M),  $\text{MgSO}_4$ . The produce was recovered by the removal of the solvent with a vacuum evaporator to yield

5  $\text{AcN}(\text{Me})\text{CH}_2\text{COOCH}_2(\text{C}_6\text{H}_5)$  (8).

#### Example 9

(Scheme 2, Step 9)

Following the procedure described by S. Scheibye et al., Bull Soc Chim Belg (1978) 87:229, p-methoxyphenylthionophosphine sulfide (Lawesson's Reagent) was added to a solution of 8 in benzene, and the mixture heated to reflux for 10 min. After cooling, the mixture was washed with saturated  $\text{NaHCO}_3$  solution, citric acid, water, saturated  $\text{NaCl}$  solution, and dried over

15 anhydrous  $\text{MgSO}_4$ . After the solvent was removed by vacuum evaporation, the residue was crystallized from ethyl acetate-hexane to provide  $\text{MeC}(=\text{S})\text{N}(\text{Me})\text{CH}_2\text{COOCH}_2(\text{C}_6\text{H}_5)$  (9).

20

#### Example 10

(Scheme 2, Step 10)

A solution of N-thioacetyl sarcosine benzylester (2, 10 mM) in methanol (20 ml) was surrounded

25 by a water bath of room temperature, and 1 N  $\text{NaOH}$  (22 ml) was added with stirring. The mixture was left at room temperature for 2 hr and treated with strongly acidic ion exchangers. After the solvent was removed by vacuum evaporation, the residue was crystallized from EtOAc-hexane to yield  $\text{MeC}(=\text{S})\text{N}(\text{Me})\text{CH}_2\text{COOH}$  (10).

30

35

Example 11


(Scheme 2, Step 11)

An equimolar mixture of 6, 10, N-ethyl-N'-3-dimethylaminopropylcarbodiimide hydrochloride (EDC), and  
 5 1-hydroxybenzotriazole (HOBT) in dimethylformamide (DMF) were reacted at 0°C overnight. The mixture was treated with mixed ion exchangers and the solvent removed by vacuum evaporation. The residue was crystallized from ethanol and water to yield the condensation product  
 10  $\text{MeC(=S)N(Me)CH}_2\text{CO(Ala)}_2\text{NHCH}_2\text{NH-Boc}$  (11).

Example 12

(Scheme 2, Step 12)

Compound 11 was dissolved in acetic acid and a  
 15 molar excess of iodomethane added. After the mixture was stirred for 6 hr the solvent, the unreacted MeI was removed with a vacuum rotary evaporator. It was important to use acid acetic as solvent to stabilize the product in this step. Other solvents, such as DMF or THF  
 20 resulted in a considerable side product formation. The reaction yielded




25

Example 13

(Scheme 2, Step 13)

Compound 12 was treated with trifluoroacetic acid (TFA) for 10 min, and the solvent removed by vacuum  
 30 evaporation to provide




35

Example 14

(Scheme 2, Step 14)

Compound 13 was dissolved in DMF at a concentration less than 10 mM and treated with weakly basic anion exchange resin. After the solvent was removed by vacuum evaporation the residue was purified with HPLC to yield



a compound of the invention.

15

Example 15

(Scheme 3, Step 1)

Following the procedure described by G.J. Atwell et al., Synthesis 1984:1032. Ethylene diamine (0.26 M) was dissolved in water containing bromocresol green as indicator. Methanesulfonic acid (0.48 M) in water 50 ml) was added until a blue to pale yellow color was achieved. The solution was diluted with EtOH (140 ml), vigorously stirred, and treated at room temperature with solutions of benzyloxycarbonyl chloride (Cbz-Cl, 0.23 M) in dimethoxyethane (DME, 50 ml) and 50% aqueous KOAc. After the additions were complete the mixture was stirred for 1 hr, and volatiles were removed in vacuo. The residue was shaken with water (500 ml) and filtered to remove the bis-derivative. The filtrate was washed with benzene, basified with 40% NaOH, and then extracted with benzene. The organic layer was washed with saturated aqueous NaCl, dried with MgSO<sub>4</sub>, and dried in vacuo to yield Cbz-NHCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> (15).

35



Example 16

(Scheme 3, Step 2)

Compound 15 was dissolved in ethyl acetate and an equimolar amount of t-butyl pyrocarbonate slowly added. The solution was dried with a vacuum rotary evaporator and the residue crystallized from ethyl acetate-hexane to yield Cbz-NHCH<sub>2</sub>CH<sub>2</sub>NH-Boc (16). (See P.L. Barker et al. J. Org. Chem 46:2455-2465 (1980)).

Example 17

(Scheme 3, Step 3)

Following the procedure described in Example 4 above, compound 16 was hydrogenolyzed to provide NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH-Boc (17). (See P.L. Barker et al. J. Org. Chem 46:2455-2465 (1980)).

Example 18

(Scheme 3, Step 4)

Following the procedure described in Example 5 above, compounds 17 and 1 were condensed in EtOH to provide Cbz-Ala-CONHCH<sub>2</sub>CH<sub>2</sub>NH-Boc (18).

Example 19

(Scheme 3, Step 5)

Following the procedure described in Example 4 above, compound 18 was hydrogenolyzed to provide NH<sub>2</sub>-Ala-CONHCH<sub>2</sub>CH<sub>2</sub>NH-Boc (19).

Example 20

(Scheme 3, Step 6)

Following the procedure described in Example 5 above, compounds 19 and 1 were condensed in EtOH to provide Cbz-Ala-Ala-CONHCH<sub>2</sub>CH<sub>2</sub>NH-Boc (20).

-55-

Example 21

(Scheme 3, Step 7)

Following the procedure described in Example 4 above, compound 20 was hydrogenolyzed to provide NH<sub>2</sub>-Ala-Ala-CONHCH<sub>2</sub>CH<sub>2</sub>NH-Boc (21).

Example 22

(Scheme 3, Step 8)

Following the procedure described in Example 7 above, MeNHCH<sub>2</sub>COOH is esterified with benzyl alcohol to provide MeNHCH<sub>2</sub>COOBz (22).

Example 23


(Scheme 3, Step 9)

Following the procedure described in Example 8 above, compound 22 is acetylated to provide AcNH(Me)CH<sub>2</sub>COOBz (23).

Example 24

(Scheme 3, Step 10)

Following the procedure described in Example 9 above, compound 23 is converted to

Example 25

(Scheme 3, Step 11)

Following the procedure described in Example 10 above, compound 24 is saponified to yield




35

Example 26


(Scheme 3, Step 12)

Following the procedure described in Example 11  
above, compounds 21 and 25 are condensed to provide

Example 27


(Scheme 3, Step 13)

Following the procedure described in Example 12  
above, compound 26 is S-methylated with MeI to provide

Example 28

(Scheme 3, Step 14)

Following the procedure described in Example 13  
above, compound 27 was deprotected by hydrolyzing the Boc  
group with TFA, thus providing



30


35

-57-

Example 29

(Scheme 3, Step 15)

Following the procedure described in Example 14 above, compound 28 is cyclized with a weakly basic anion exchange resin to provide



a compound of the invention. Compound 29 exhibits a Type 1 reverse turn structure, as determined by nmr. Also crystal structure determined.

Example 30

(Scheme 5, Step 1)

12 mmols methyl 5,5-dimethoxypentanoate (Stevens, R.V. et al., J Am Chem Soc (1979) 7054) were dissolved in 20 ml 50% aqueous methanol. 16 mmols NaOH were added and the mixture was stirred for 2 hr at room temperature. The solvent was then evaporated, the residue layered with 30 ml EtOAc, and the sodium salt neutralized with ice-cold 1 N HCl. The aqueous phase was extracted with an additional 20 ml EtOAc, the organic extracts combined and dried over K<sub>2</sub>CO<sub>3</sub>. The product was filtered and the solvent evaporated to provide 5,5-dimethoxypentanoic acid.

Carbonyldiimidazole (Im<sub>2</sub>CO, 10 mmols) was added to a solution of 5,5-dimethoxypentanoic acid (10 mmole) in acetonitrile (13 ml), and the mixture stirred at room temperature for 40 min. Leucine benzyl ester tosylate (11 mmols) was added, followed by diisopropylethylamine (11 mmols), and the mixture stirred overnight at room temperature. The solvent was evaporated, and the residue dissolved in ethylacetate (50 ml), washed with ice-cold 1 M citric acid (20 ml), 1 M NaHCO<sub>3</sub>, (20 ml) and brine (20 ml). The product was

dried over  $\text{MgSO}_4$ , the solvent evaporated, and the residue chromatographed on silica gel to provide  
 $(\text{MeO})_2\text{CH}(\text{CH}_2)_3\text{CONHCH}(\text{i-Bu})\text{COOBz}$  (32).

5

Example 31

(Scheme 5, Step 2)

Compound 32 (10 mmoles) was dissolved in 15 ml MeOH. 50 mg 10% Pd/C were added, and the mixture was hydrogenolyzed for 20 min at room temperature under 1 atm  
10  $\text{H}_2$  pressure. The mixture was then filtered and the solvent evaporated to provide  
 $(\text{MeO})_2\text{CH}(\text{CH}_2)_3\text{CONHCH}(\text{i-Bu})\text{COOH}$  (33).

15

Example 32

(Scheme 5, Step 3)

N-aminoglycine ethylester HCl (32 mmoles) was neutralized with  $\text{Na}_2\text{CO}_3$  (32 mmoles), extracted with  $\text{CH}_2\text{Cl}_2$ , and dried over  $\text{K}_2\text{CO}_3$ . Then, acetone (10 ml) was added, and the  $\text{CH}_2\text{Cl}_2$  evaporated. An additional 20 ml  
20 acetone was added, and the solvent evaporated. The residue was then dissolved in  $\text{CH}_2\text{Cl}_2$  (20 ml), dried over  $\text{MgSO}_4$ , and the solvent evaporated to yield  
 $\text{Me}_2\text{C}=\text{NNHCH}_2\text{COOEt}$  (34).

25

Example 33

(Scheme 5, Step 4)

Compound 34 was added to 1.1 equivalents of Boc-ala anhydride in THF and allowed to react for 12 hr. The crude product was dissolved in  $\text{CH}_2\text{Cl}_2$ , 1 N HCl added,  
30 and stirred for 2 hr. The phases were then separated, and the  $\text{CH}_2\text{Cl}_2$  evaporated to obtain  
 $\text{Boc-NHCH}(\text{Me})\text{CON}(\text{NH}_2)\text{CH}_2\text{COOEt}$  (35).

35

Example 34

(Scheme 5, Step 5)

Compound 35 (20 mmoles) in Et<sub>2</sub>O (20 ml), was treated with NaHCO<sub>3</sub> (25 moles), Cbz-Cl (25 mmoles), and 3 drops DMF in 5 ml H<sub>2</sub>O. The mixture was stirred vigorously overnight. Then 1 ml pyridine was added to destroy excess Cbz-Cl. The Et<sub>2</sub>O phase was washed with 1 N HCl, 1 N NaHCO<sub>3</sub>, and brine, dried, and the solvent evaporated. The residue was crystallized from Et<sub>2</sub>O/hexane to provide Boc-NHCH(Me)CON(NH-Cbz)CH<sub>2</sub>COOEt (36).

Example 35

(Scheme 5, Step 6)

The Boc protecting group was removed by reacting compound 36 with 4 N HCl/dioxane for 30 min at room temperature. The excess dioxane/HCl was then evaporated to provide NH<sub>2</sub>CH(Me)CON(NH-Cbz)CH<sub>2</sub>COEt·HCl (37).


Example 36

(Scheme 5, Step 7)

Ethyl(dimethylaminopropyl)carbodiimide (8 mmoles) was added to an ice-cooled solution of compound 31 in CH<sub>3</sub>CN (15 ml), and the mixture stirred for 1 hr at 0°. Then compound 37 (8 mmoles) was added, followed by diisopropylethylamine (8 mmoles). The mixture was stirred overnight at 5°C, and the solvent evaporated. The residue was dissolved in EtOAc (30 ml), washed with ice-cold 1 M citric acid (15 ml), 1 M NaHCO<sub>3</sub> (15 ml) and brine (15 ml), and dried overnight over MgSO<sub>4</sub>. The

-60-


solvent was evaporated, and the product chromatographed on silica gel to provide



### Example 37

(Scheme 5, Step 8)

10 Compound 38 (3 mmoles) in MeOH (15 ml) were hydrogenolyzed over 20 mg 10% Pd/C for 20 min at room temperature and under 1 atm H<sub>2</sub> pressure. The mixture was then filtered, and the solvent evaporated to provide



### Example 38

(Scheme 5, Step 9)

20 Compound 39 from Example 37 was dissolved in 100 ml CH<sub>3</sub>CN. Then BF<sub>3</sub>·Et<sub>2</sub>O (10 μl) was added, and the solution stirred overnight at room temperature. Alternatively, compound 39 (0.1 mmol) was dissolved in 1  
 25 liter of acetonitrile and p-toluene sulfonic acid (0.1 mmol) was added. After 1 hour the solvent was removed, the product dissolved in ether and washed with water and dried. The product was then treated with 2 ml  
 30 trifluoroacetic acid for 20 min., concentrated and purified on a semipreparative G<sub>8</sub> reversephase HPLC column. The solvent was then evaporated, and the product chromatographed on a semi-preparative C<sub>4</sub> reverse phase HPLC column to provide the compound of the invention 40.


35

Example 39

## (Preparation of EGF Analogs)

A synthetic polypeptide mimic of epidermal growth factor activity is prepared as follows:

5 (A) Class 1 Mimic: A compound of the formula



10 is prepared, following the procedures set forth in Examples 15-28. The compound is then cyclized following the procedure set forth in Example 29 to provide a reverse-turn stabilized EGF peptide.

15 (B) Class 2 Mimic: A compound of the formula  
 $(\text{MeO})_2\text{CH}(\text{CH}_2)_3\text{CON-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-CON-CH}_2\text{COOEt}$   
 $\quad\quad\quad |$   
 $\quad\quad\quad \text{NH}_2$

20 is prepared according to the procedures set forth in Examples 30-37, and is cyclized following the procedure of Example 38 to provide a  $\beta$ -hairpin.

(C) Extended Class 2 Mimic: An extended class 2 EGF polypeptide analog is prepared similarly, by cyclizing a compound of the formula  $(\text{MeO})_2\text{CH}(\text{CH}_2)_3\text{CON-Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys-CON}(\text{NH}_2)\text{-CH}_2\text{COOEt}$ .

Example 40

## (Preparation of Malarial Antigens)

30 A synthetic polypeptide vaccine for malaria was recently tested in humans by Herrington et al., Nature (1987) 328:257. However, it proved to be only partially effective. Improvements in the potency of the vaccine could be achieved by the conformation restriction of the synthetic polypeptide, which is based upon a repeating

35



tetrapeptide (Asn-Ala-Asn-Pro)<sub>3</sub>. According to Chou-Fassam analysis (Chou et al., Biochem (1974) 13:222, the frame-shifted sequence Asn-Pro-Asn-Ala should have a strong tendency to form reverse turns in native proteins.


- 5 The reverse turn can be locked into place by replacing putative amide-amide hydrogen bonds between Asn sidechains around proline with class 1 or class 2 hydrogen bond mimics.

(A) Class 1 Mimic: A compound of the formula

10



15




p = 1, 2

(where (aa)<sub>n</sub> and (aa)<sub>m</sub> are each independently amino acid sequences of 1-12 amino acids or R\*, where R\* is alkyl of 1-6 carbons, phenyl, naphthyl, benzyl, or -NH<sub>2</sub>) is prepared following the procedures set forth in Examples 1-29, and is cyclized to form a polypeptide analog suitable for malarial vaccination having the following structure:

25



30



p = 1, 2

The compound is emulsified in a non-toxic vegetable oil and sterile water for injection, and is

35

administered conventionally through intramuscular injection.

#### Solid Phase Synthesis

5                Various types of solution synthesis processes  
can be used in order to insert the hydrogen bond mimics  
of the present invention into peptides. The inclusion of  
Class 1 and Class 2 hydrogen bond mimics within solution  
10 synthesis procedures were disclosed above. These methods  
of synthesis were designed so that they could eventually  
be carried out on solid supports. The solid phase  
synthesis techniques are now disclosed below.

              It is desirable to carry out solid phase  
synthesis procedures in connection with and including the  
15 hydrogen bond mimics because a number of advantages can  
be obtained. Specifically, the use of solid phase  
synthesis eliminates the need for purification, often  
eliminates intractable intermediates, and can  
significantly reduce the amount of time and labor  
20 required in order to obtain a given final product.  
Accordingly, in many situations, solid phase synthesis  
techniques are preferred over solution synthesis  
procedures.

              New synthetic procedures are described herein  
25 for introducing Class 2 mimics into peptides on solid  
supports. Such procedures have significantly enhanced  
abilities with respect to utilizing Class 2 mimics in  
peptides. These procedures have been adapted to multiple  
peptide synthesis and employed to insert a variety of  
30 amino acids and variable numbers of amino acids between  
the hydrogen bond mimics. It is important to note that  
these solid phase reaction protocols can be adapted for  
use in connection with automated peptide synthesis  
machines.


Example 41

The following is a detailed description of the use of the solid phase synthesis technology of the present invention to insert Class 2 hydrogen bonds into peptides on solid supports. The results of the synthesis provide a new modified amino acid. Further, the protocol describing the insertion of a hydrazone link into the peptide is followed by a reaction scheme protocol, which should be referred to in connection with the following detailed protocol.

[(1-methylethylidene-2-Fmoc) hydrazino]acetic acid. Hydrazinoacetic acid ethyl ester (15.4 gm, 100 mmol) was dissolved in 150 ml water. Then 150 ml acetone was added and the mixture heated to reflux and cooled to room temperature. The ester was then hydrolyzed by adding sodium hydroxide (8.4 g, 210 mmol) and stirring for 30 min. Then sodium carbonate (10.6 gm, 100 mmol) was added and the mixture brought to ice-cold temperature. Then Fmoc-chloride (25.9 g, 100 mmol) was slowly added with stirring over a two hour period. Stirring was continued overnight while the reaction warmed to room temperature. The reaction mixture was rotary evaporated to dryness, the product dissolved in water and precipitated by acidifying with concentrated HCl. The precipitate was refluxed briefly with acetone and crystallized from ethyl acetate-hexane to give 28.4 gm (yield = 81%). mp = 129-131. Mass analysis, elemental analysis and NMR spectroscopy confirmed the synthesis.

-65-

Reaction Scheme for Example 41  
Insertion of Hydrogen Bond Mimic  
into Peptides on Solid Support



SUBSTITUTE SHEET

Application of the Invention to Known PeptidesA. Producing Stabilized Synthetic HIV Peptides.

The above examples describe reaction schemes and methods of synthesizing peptides with the covalent bonds (class I or class II) in solution and on solid supports. In order to make use of these methods of synthesis the following describes how predictive algorithms can be employed to identify putative hydrogen bonds in a particular peptide of particular interest, specifically, HIV peptides. Producing such peptides with stabilized three-dimensional structures using the methods of the invention provides structures which can be used as diagnostic reagents for AIDS, panning reagents for the identification and isolation of human antibodies to HIV and synthetic vaccines produced by combining the stabilized peptides with pharmaceutically acceptable carriers.

One of the known peptides of HIV is the peptide gp120. The V3 loop of the gp120 protein has been identified as a neutralizing epitope (see W.G. Robey et al. Science 234:7023 (1987) and evidence has been cited to support the claim that gp120 is the principle neutralizing epitope (G.J. LaRosa et al., Science 249:932 (1990)).

A strong correlation has been observed between the presence of antibodies to peptides from the V3 loop in seropositive mothers and the absence of disease in their children (see P. Rossi et al. P.N.A.S. 86:8055 (1989)). These peptides map to the predicted hairpin and helix regions discussed below. The antibodies to either or both of the predictive loop and helix regions could be protective against HIV. More specifically, the present invention could be used to produce the loop and helix regions of the gp120 peptide and delivered to a patient

in order to cause the patient to generate antibodies to these proteins and thereby provide a vaccine with respect to the AIDS virus.

5       The V3 loop is formed by a disulphide bridge  
between positions 303 and 338 of the gp120 protein. A  
particular type of prediction known as the GORBTURN  
predictions can be used in order to create predictions  
for the use consensus sequence for the commonly found  
HIVMN strain. These predictions for the consensus  
10       sequence are shown in Tables 2 and 3 below.

15

20

25

30

35

TABLE 2

Consensus Sequence for V3 Loop

Gorbtturn Prediction of B-Turns

LINE	RESIDUE SEQUENCE	STRENGTHS OF PREDICTION			B-TURN PREDICTED
		I	II	NON-SPEC	
1	CYS THR ARG PRO	-0.96	-0.99	-0.35	
2	THR ARG PRO ASN	-0.80	-0.98	-0.93	
3	ARG PRO ASN ASN	-0.15	-0.75	0.09	Non-specific B-turn
4	PRO ASN ASN ASN	-0.49	-0.78	0.29	Non-specific B-turn
5	ASN ASN ASN THR	0.37	-0.91	0.75	Non-specific B-turn
6	ASN ASN THR ARG	-0.37	-0.99	-0.67	
7	ASN THR ARG LYS	-0.07	-0.97	-0.61	
8	THR ARG LYS SER	-0.63	-0.93	-0.74	
9	ARG LYS SER ILE	-0.71	-0.99	-0.37	
10	LYS SER ILE HIS	-0.88	-1.00	-0.88	B-strand
11	SER ILE HIS ILE	-0.73	-0.99	-0.45	B-strand
12	ILE HIS ILE ILE	-0.98	-1.00	-0.86	B-strand
13	HIS ILE ILE GLY	-0.57	-1.00	-0.87	B-strand
14	ILE ILE GLY PRO	-1.00	-0.95	0.65	B-strand
15	ILE GLY PRO GLY	0.94	0.99	0.84	B-strand
16	GLY PRO GLY ARG	-0.73	6.53	-0.17	Type 2 turn
17	PRO GLY ARG ALA	-0.89	-0.94	-0.45	HAIRPIN

The strength of prediction is a measure of how strongly a turn is predicted. Positive values indicate a turn type prediction; the larger the value, the stronger the turn prediction. When more than one turn type is predicted, then the turn type with the greatest strength is selected. For further details, please read the documentation.

LINE	RESIDUE SEQUENCE	STRENGTHS OF PREDICTION		B-TURN PREDICTED
		I	II	
19	ARG ALA PHE TYR	-0.72	-0.99	B-strand B-strand
18	GLY ARG ALA PHE	-0.59	-1.00	
20	ALA PHE TYR THR	-0.91	-0.95	
21	PHE TYR THR THR	-0.83	-0.98	
22	TYR THR THR GLY	-0.29	-0.99	
23	THR THR GLY GLU	-0.71	-0.47	N-Cap N1
24	THR GLY GLU ILE	-0.83	-0.98	
25	GLY GLU ILE ILE	-0.88	-1.00	
26	GLU ILE ILE GLY	-0.84	-1.00	
27	ILE ILE GLY ASP	-0.91	-0.79	
28	ILE GLY ASP ILE	-0.88	-0.99	Helix
29	GLY ASP ILE ARG	-0.89	-1.00	
30	ASP ILE ARG GLN	-0.17	-0.98	
31	ILE ARG GLN ALA	-0.88	-0.97	
32	ARG GLN ALA HIS	-0.93	-1.00	
33	GLN ALA HIS CYS	-0.70	-0.75	Helix
34	ALA HIS CYS ASN	-0.84	-0.91	
35	HIS CYS ASN ILE	-0.38	-0.99	
36	CYS ASN ILE SER	-0.83	-1.00	
37	ASN ILE SER ARG	-0.37	-0.99	
38	ILE SER ARG ALA	-0.78	-0.88	Helix
39	SER ARG ALA LYS	-0.64	-0.97	
40	ARG ALA LYS TRP	-0.63	-0.99	
41	ALA LYS TRP ASN	-0.62	-1.00	
42	LYS TRP ASN ASN	-0.76	-0.94	
43	TRP ASN ASN THR	-0.40	-1.00	
44	ASN ASN THR LEU	-0.01	-1.00	



TABLE 3

## Consensus Sequence for V3 Loop

Gorbtturn Prediction of B-Turns

LINE	RESIDUE SEQUENCE	STRENGTHS OF PREDICTION			B-TURN PREDICTED
		I	II	NON-SPEC	
1	GLU GLU VAL VAL	-0.93	-1.00	-0.92	Helix
2	GLU VAL VAL ILE	-0.98	-1.00	-0.94	Helix
3	VAL VAL ILE ARG	-0.98	-1.00	-0.94	B-strand
4	VAL ILE ARG SER	-0.90	-0.98	-0.68	B-strand
5	ILE ARG SER GLU	-0.73	-0.96	-0.58	B-strand
6	ARG SER GLU ASN	-0.49	-0.99	-0.47	
7	SER GLU ASN PHE	0.93	-0.94	-0.19	B-strand
8	GLU ASN PHE THR	-0.78	-0.99	-0.63	
9	ASN PHE THR ASP	-0.55	-0.99	-0.97	
10	PHE THR ASP ASN	-0.12	-0.98	-0.79	
11	THR ASP ASN ALA	-0.43	-0.75	-0.14	Helix
12	ASP ASN ALA LYS	-0.60	-0.99	-0.70	
13	ASN ALA LYS THR	-0.07	-0.98	-0.79	
14	ALA LYS THR ILE	-0.75	-0.99	-0.87	
15	LYS THR ILE ILE	-0.92	-1.00	-0.89	Helix
16	THR ILE ILE VAL	-0.92	-1.00	-0.91	Helix
17	ILE ILE VAL HIS	-0.97	-1.00	-0.95	B-strand
18	ILE VAL HIS LEU	-0.93	-0.98	-0.58	B-strand
19	VAL HIS LEU ASN	-0.93	-0.99	-0.91	B-strand
20	HIS LEU ASN GLU	-0.28	-0.96	-0.65	Helix
21	LEU ASN GLU SER	-0.76	-0.96	-0.57	
22	ASN GLU SER VAL	0.03	-0.99	-0.53	Type 1 turn
23	GLU SER VAL GLN	-0.84	-0.99	-0.83	
24	SER VAL GLN ILE	-0.85	-0.99	-0.78	

-71-

LINE	RESIDUE SEQUENCE	STRENGTHS OF PREDICTION		B-TURN PREDICTED
		I	II	
			NON-SPEC	
25	VAL GLN ILE ASN	-0.95	-1.00	
26	GLN ILE ASN CYS	-0.62	-0.89	
27	ILE ASN CYS THR	-0.82	-0.92	B-strand
28	ASN CYS THR ARG	-0.42	-1.00	B-strand
29	CYS THR ARG PRO	-0.96	-0.99	
30	THR ARG PRO ASN	-0.80	-0.98	
31	ARG PRO ASN TYR	0.02	-0.63	Non-specific B-turn
32	PRO ASN TYR ASN	-0.73	-0.96	
33	ASN TYR ASN LYS	-0.53	-0.79	
34	TYR ASN LYS ARG	-0.82	-0.91	
35	ASN LYS ARG LYS	0.22	-0.93	Type 1 turn
36	LYS ARG LYS ARG	-0.77	-0.93	
37	ARG LYS ARG ILE	-0.73	-0.98	
38	LYS ARG ILE HIS	-0.91	-1.00	
39	ARG ILE HIS ILE	-0.89	-1.00	B-strand
40	ILE HIS ILE GLY	-0.92	-1.00	B-strand
41	HIS ILE GLY PRO	-0.98	-0.99	B-strand
42	ILE GLY PRO GLY	-0.94	-0.99	B-strand
43	GLY PRO GLY ARG	-0.73	6.53	Type 2 turn
44	PRO GLY ARG ALA	-0.89	-0.94	
45	GLY ARG ALA PHE	-0.59	-1.00	
46	ARG ALA PHE TYR	-0.72	-0.99	
47	ALA PHE TYR THR	-0.91	-0.95	
48	PHE TYR THR THR	-0.83	-0.98	
49	TYR THR THR LYS	-0.75	-0.99	
50	THR THR LYS ASN	-0.47	-0.98	B-strand
51	THR LYS ASN ILE	-0.34	-0.71	B-strand
52	LYS ASN ILE GLY	-0.77	-1.00	Non-specific B-turn
53	ASN ILE GLY THR	-0.55	-0.94	
54	ILE GLY THR ILE	-0.94	-1.00	
55	GLY THR ILE ARG	-0.91	-1.00	B-strand

HAIRPIN

-72-

LINE	RESIDUE SEQUENCE	STRENGTHS OF PREDICTION		B-TURN PREDICTED	
		I	II	NON-SPEC	
56	THR ILE ARG GLN	-0.52	-0.95	-0.63	B-strand N-Cap.
57	ILE ARG GLN ALA	-0.88	-0.97	-0.70	B-strand N1
58	ARG GLN ALA HIS	-0.93	-1.00	-0.90	Helix
59	GLN ALA HIS CYS	-0.70	-0.75	-0.79	B-strand
60	ALA HIS CYS ASN	-0.84	-0.91	-0.97	Helix
61	HIS CYS ASN ILE	-0.38	-0.99	-0.37	Helix
62	CYS ASN ILE SER	-0.83	-1.00	-0.72	Helix
63	ASN ILE SER ARG	-0.37	-0.99	-0.45	
64	ILE SER ARG ALA	-0.78	-0.88	-0.38	
65	SER ARG ALA LYS	-0.64	-0.97	-0.81	
66	ARG ALA LYS TRP	-0.63	-0.99	-0.92	Helix
67	ALA LYS TRP ASN	-0.62	-1.00	-0.95	
68	LYS TRP ASN ASP	-0.78	-0.90	-0.78	
69	TRP ASN ASP THR	-0.24	-1.00	-0.41	
70	ANS ASP THR LEU	0.43	-1.00	-0.72	Helix
71	ASP THR LEU ARG	-0.59	-0.99	-0.78	Helix
72	THR LEU ARG GLN	-0.56	-0.79	-0.77	Helix
73	LEU ARG GLN ILE	-0.77	-0.98	-0.76	Helix
74	ARG GLN ILE VAL	-0.96	-1.00	-0.89	Helix
75	GLN ILE VAL SER	-0.94	-1.00	-0.93	Helix
76	ILE VAL SER LYS	-0.93	-0.96	-0.69	Helix
77	VAL SER LYS LEU	-0.75	-0.97	-0.83	Helix
78	SER LYS LEU LYS	-0.56	-0.98	-0.75	Helix
79	LYS LEU LYS GLU	-0.80	-0.99	-0.92	Helix
80	LEU LYS GLU GLN	-0.46	-0.90	-0.62	Helix
81	LYS GLU GLN PHE	-0.35	-1.00	-0.74	Helix
82	GLU GLN PHE LYS	-0.88	-0.98	-0.79	Helix

35

5

10

15

20

25

30

35

LINE	RESIDUE SEQUENCE	STRENGTHS OF PREDICTION			B-TURN PREDICTED
		I	II	NON-SPEC	
83	GLN PHE LYS ASN	-0.86	-0.95	-0.96	Helix
84	PHE LYS ASN LYS	-0.42	-0.26	-0.51	Helix
85	LYS ASN LYS THR	-0.72	-0.98	-0.69	Helix

The strength of prediction is a measure of how strongly a turn is predicted. Positive values indicate a turn type prediction; the larger the value, the stronger the turn prediction. When more than one turn type is predicted, then the turn type with the greatest strength is selected. For further details, please read the documentation.

The consensus sequence predictions suggest a structural motif which has also been predicted by a neural network analysis of the V3 region from 245 different HIV-1 isolates (see G.J. LaRosa et al. cited above). These algorithms predict a secondary structure motif for the V3 loop consisting of a B strand - Type II reverse turn - B strand - alpha helix. It should be noted that a B strand - type II reverse turn - B strand is a characteristic of a B-hairpin loop.

An analysis of mutational frequencies provide additional information with regards to structure. B-hairpins are often characterized by a hydrogen bonding pattern where alternate pairs of amino acids have hydrogen bonds across the strand. Mutational frequencies for amino acids in the predictive strand regions (see G.J. LaRosa et al. cited above) display a remarkable cadence consistent with a 2:2 B-hairpin structure. However, predictive algorithms and mutational analysis do not rule out the presence of other structures such as the 2:4, 3:3, 3:5, 4:4, 4:6 or other irregular B-hairpin loops for the consensus sequence RKSIHIGPGRAFYTIG and all B-hairpin structures should be considered possible until experimentation and results eliminates a possibility. Hairpin loops are classified here according to the nomenclature of B.L. Sibanda et al., J. Mol. Biol. 206:759 (1989). The predicted structures provide information with regard to where hydrogen bond mimics might be initially inserted.

The prediction for an alpha helix at the C-terminus of the V3 loop is also strengthened by the analysis of mutations in the putative N-cap and N1 positions. It has been observed that the most frequently found amino acids at the N-cap position are Ser, Asn, Gly, Asp and Thr (J.S. Richardson and D.C. Richardson, Science 240:1648 (1988). These preferences are a

consequence of the ability of the amino acid side chain to hydrogen bond to the backbone amide NH of the N2 or more preferably the N3 amino acids. This side chain to backbone hydrogen bonding stabilizes the otherwise non-hydrogen bonded backbone amide protons at the N-termini of alpha helices. It was also observed that Pro and Glu are most often found at the N1 position. The observed N-cap and N1 amino acids are often treated as helix breakers i.e. Asp and Pro and thus are not predicted to be helix by algorithms (see Tables 2, 3 above).

The HIV loop mutates frequently at the putative N-cap and N1 positions and less in the extension of the predicted helical region. Frequently, these mutations are to those favored at helix start positions adding considerable strength to the prediction for alpha helix initiation at these positions. Thus one observes Asn-Met (BH10), Thr-Ileu (NM), Asp-Ileu (SC) and Lys-Pro (HIVII) at the N-cap and N1 positions while remaining amino acids in the predicted HIV1 helices, RQAHCNISRAK remain invariant. In addition to strengthening the prediction for a helix, this analysis points out another feature which may be of use from the viewpoint of hydrogen bond mimics, namely that a side-chain to backbone hydrogen bond is predicted from the N-cap to the N2 or N3 position.

To summarize, predictive algorithms and mutational analyses lead to a self consistent and detailed structural model of the loop region with a hydrogen bonding pattern that provides a rational starting point for the insertion of hydrogen bond mimics. A predicted hydrogen bonding map for a consensus sequence (G.J. LaRosa et al., referenced above) for the loop region is shown in Figure 3.

The predicted structure displays a 2:2 B hairpin structure. However, it is not intended to rule

out other potential loops and B-hairpin structures and is merely meant to be illustrative. In addition, the longest potential alpha helix is indicated. It could be shorter with a C-terminus at Asn, Arg or Lys or at other positions.

Both the Class I and Class II hydrogen bond mimics have been employed to conformationally restrict V3 loop peptides as well as other peptides to smaller loop and alpha helical structures. Some of these peptides which include V3 loop peptides were synthesized using methods of synthesis in solution described above while others including the V3 helix peptides were synthesized by adding a preformed [Leu-Ala]NucSite to a peptide on a solid support (also described above). Either method can be used to synthesize helical peptides.

Each of the hydrogen bonds in the proposed B hairpin can be replaced with either the Class I or the Class II mimic. The Class I mimic replaces hydrogen bonds in the (i, i + n) sense while the Class II mimic acts in the alternative (i + n, i) sense.

Each structure can be tagged at the base of the loop with cysteine or other linkers for attachment to supports of interest i.e. maleimide activated BSA or KLH for immunizations. Modified versions of the Class I linker has been prepared for this purpose.

#### Example 42

The compound  $\text{Cbz-NHCH}_2\text{CONHCH}_2\text{COBz}$  is synthesized by coupling  $\text{Cbz-NHCH}_2\text{CH}_2\text{COOH}$  to the glycine benzyl ester ( $\text{NH}_2\text{CH}_2\text{COOBz}$ ) using standard procedures with an equivalent of DCC in DMF.

-77-

Example 43

The compound FmocNHCH(CH<sub>2</sub>NHBOC)COOH is synthesized by first making Cbz-NHCH(CH<sub>2</sub>NH-Boc)CO<sub>2</sub>H according to the procedure of M. Waki et al. Synthesis, pp. 266-267 (1981). The Cbz group is removed with 10% Pd-C/ hydrogen gas in ethanol and then treated with commercially available Fmoc-Cl using standard procedures to give FmocNHCH(CH<sub>2</sub>NHBOC)COOH.

10

Example 44

The compound FmocNHCH<sub>2</sub>CH(NHBoc)COOH is synthesized by first making Boc-NHCH(CH<sub>2</sub>NH<sub>2</sub>)COOH according to the method of M. Waki et al. (cited above). This product is treated with Fmoc-Cl to give FmocNHCH<sub>2</sub>CH(NHBoc)COOH using procedures shown in Scheme 6 below.

15

20

25

30


35




- 78 -

## Scheme 6

Two linkers, Fmoc-NHCH



were synthesized according to the following scheme.



SUBSTITUTE SHEET

The compounds of Examples 43 and 44 were used to incorporate the Class I mimic into peptides on solid supports utilizing the procedures outlined in Scheme 7 below.

5

10

15

20


25

30

35

## Scheme 7

## Synthesis of cyclic peptide turns on solid supports




These procedures utilize standard Fmoc chemistry for the initial coupling of FmocLeu to Rink's amide resin followed by the sequential coupling of either Compounds of Examples 43 or 44, FmocALA and FmocALA. The peptide is then capped with acetyl thiosarcosine. Coupling is carried out using a standard PyBOP/HOBt/DIEA coupling scheme. Final cyclization is achieved by treating the capped peptide on the solid support with methyl iodide in acetic acid for 20 hours. The resin is then washed and the activated precyclic intermediate cleaved from the resin with 10% trifluoroacetic acid/methylene chloride and concentrated by rotary evaporation. The final Boc protecting group on the cleaved peptide is removed with trifluoroacetic acid in 5 min and the peptide concentrated by rotary evaporation. The activated precyclic is dissolved in DMF and treated with BioRad AG4-X4 anion exchange resin which frees the amine for cyclization. After filtration to remove resin, the product is concentrated and purified by HPLC.

The mass spectrum of the isolated products from syntheses with either compounds of Examples 43 or 44 were identical to that for the expected cyclized product. 1D NMR spectra for both compounds were consistent with the incorporation of a Class 1 mimic. The 1D NMR spectrum for the compound incorporating compound 3 was of the pattern expected for a Type 1 reverse turn. However, the NMR spectrum for the cyclic peptide formed with compound of Example 44 was not characteristic of a Type 1 reverse turn. It is likely that both links can be used in larger loops.

#### Example 45

The compound  $\text{FmocNHCH}_2\text{CH}_2\text{CSNHCH}_2\text{CH}_2\text{COOH}$  is synthesized according to Scheme 8. First  $\text{CbzNHCH}_2\text{CH}_2\text{NH}_2$  is synthesized according to P.L. Barker et al. J. Org. Chem 46: 2455-2465 (1980).

- 82 -

Scheme 8

-83-

The initial compound is mixed with commercially available  $\text{ClCOCH}_2\text{CH}_2\text{COOC}_2\text{H}_5$  in DMF to give  $\text{CbzNHCH}_2\text{CH}_2\text{NHCOC}_2\text{H}_5$ . This product is then hydrolyzed and treated with Fmoc Cl to give

5  $\text{FmocNHCH}_2\text{CH}_2\text{NHCOC}_2\text{H}_5$ . This product is treated with Lawesson's reagent to give the thioamide. Then the ethyl ester is hydrolyzed with one equivalent of sodium hydroxide in ethanol to give the final product. The product has been identified by mass spectroscopy and NMR.

10

#### Example 46

Compound 6 of Example 6 is used for the introduction of the Class I link into peptides on solid support (Scheme 9).

15

20

25

30

35

- 84 -

Scheme 9

5

10


15

20

25


30

35



SUBSTITUTE SHEET

The initial target is referred to here as HIV compound 1.



Compound 6 linked to Rink's amide resin using DIC and HOBT. The compound is then extended with amino acids utilizing standard Fmoc chemistry already described (PyBOP/HOBT/DIEA). The final amino acid is freed of its Fmoc group. The thioamide is activated with methyl iodide/acetic acid. The addition of basic ion exchange resin then cyclizes the peptide on the solid support. One advantage of the method is that standard Boc/But side chain protection can be used for protecting amino acids in these reactions. These protecting groups are stable to acetic acid. Also, any basic amino groups, i.e. N-terminal amino acid will be protonated and protected from methylation. The cyclic peptide product is then cleaved from the resin and side chains deprotected with 5%



water/95% trifluoroacetic acid and the final product purified by HPLC.

#### Class II Mimics

5           Figure 4 shows Class II mimic which are conformationally restricted HIV peptides. These peptides are referred to as HIV compounds 2, 3, 4, 5 and 6.

          These sequences use SISI at the N-terminus rather than the consensus sequence, SIHI, or the HIV MN sequence RIHI. The HIV peptides shown above were synthesized on solid supports utilizing the method described above. The only difference in the procedures is that FmocGly chloride is used in place of FmocAla chloride and that the longer amino acid sequences  
10           corresponding to the HIV sequences were incorporated between J and Z. J is 5,5-dimethoxypentanoic acid which is described in Example 30. Numerous variations on this theme can be imagined using different mutant sequences, linked together at different positions.

20           All products gave the correct mass by mass spectroscopy. A signal corresponding to that expected for the N-CH proton was apparent in 1D NMR spectra HIV(1) (4) and (5) above. Signals from Phe and/or Tyr overlap this signal in 1D NMR spectra for HIV (2) above; insufficient quantities were available for examining the  
25           NMR spectrum for HIV (3) above. A preliminary examination of temperature coefficients for the amide NH protons of HIV (4) above reveal them to be > 6 ppb per K; this indicates that the loop as constituted is highly  
30           flexible. The introduction of further constraints i.e. diethylglycine-Z in place of GZ might be used to decrease the flexibility.

Example 47

[LeuAla]NucSite was synthesized by treating compound 40 (70 mg) with NaOH (15 mg) in 50% ethanol-water (20 ml) with stirring for 2.5 hr. The reaction mixture was then acidified with prewashed Dowex 50W-X4 cation exchange resin for 15 min, filtered, concentrated and lyophilized to yield 65 mg of product. The primary structure was confirmed by high resolution mass spectroscopy and NMR.

Example 48

Compound HIV (6) above was synthesized by first using standard Fmoc chemistry (PyBOP/HOBt/DIEA) to give ARQAHC(Acm)NISRAKC-Rink amide resin. Then

[LeuAla]NucSite was linked to the peptide chain on the resin using the standard coupling reaction. The peptide was cleaved from the resin as previously described and protecting groups removed with three rounds of treatment with 5% water/95% trifluoroacetic acid for 1 hr and precipitation of the peptide with ether. The peptide is then purified to homogeneity by HPLC and its primary structure confirmed by mass spectroscopy and 1D NMR. The 1D NMR spectrum is characteristic of a peptide that has been helicalized.

Biological Tests on the HIV Peptides

The compounds HIV (3) and HIV (5) were found to bind to three murine monoclonals which also bind HIV. At least one of these monoclonals have been found to protect in monkey challenge experiments with HIV. The compounds HIV (3), (5) and (6) have been shown to react positively using ELISA with sera from a patient with AIDS. HIV (5) has been used to isolate human Fabs from combinatorial libraries by panning. Previous attempts to isolate human Fabs to this critical epitope using peptides had not

-88-

worked. These Fabs could provide a component for engineered human Mabs that could play a role in the passive immunotherapy of AIDS patients. Each and all of the compounds HIV (1)-(6) are potential synthetic vaccines for protection against HIV. Each has been linked via Cys to maleimide activated protein carriers for immunization purposes.

10           B. Synthesizing Synthetic Malaria Peptides

The synthesis technology described above for producing stabilized peptides which have a desired 3-dimensional conformation capable of binding to an antibody can be used to produce a synthetic peptide useful as an effective malaria vaccine. More specifically, the invention can be used to produce a malaria vaccine composed of constrained peptides corresponding to neutralizing epitopes on various stages of *P. falciparum* malaria which is a parasite that infects hundreds of millions of people each year.

In order to obtain the desired results the invention is used to produce a peptide which acts as a multistage vaccine. The primary components of a multistage vaccine include: (1) neutralizing epitopes from the infective sporozoite; (2) neutralizing epitopes from the liver and blood stage merozoites; (3) cytoadherence antigens; (4) neutralizing epitopes from gametocytes; and (5) proteins on ookinetes required for the transmission to mosquitoes. Blocking transmission limits the propagation of escape mutants which are generated under immune pressure from other components of the vaccine.

By using the synthesis technology of the present invention it is possible to produce shaped peptides which are constrained to mimic the 3-dimensional

structure of malaria epitopes which act as better antigens and mutagens since antigen-antibody reactions are anticipated in a manner so as to significantly improve the desired shape complementarity. The results are obtained by producing "shaped peptides" which implies peptides which have been shaped in a 3-dimensional configuration so as to have a targeted confirmation. Other terms used herein include peptide mimics, protein mimics and mimetopes.

In order to produce a biologically useful malaria vaccine which is a shaped peptide which binds to malaria antibodies one must use an effective and reliable method for shaping peptides. Such a method has been described above. Over 80% of the amino acids in globular proteins fall within the common secondary structures which include the alpha helix, reverse turn, omega loops and beta sheets which have been shown above. Reverse turns and loops are frequently located on protein surfaces. As described above in detail, the present invention involves replacing weak structural defining hydrogen bonds with covalent mimics. Specific protocols have been developed for inserting hydrogen bond mimics into peptides on solid supports. This methodology is more efficiently utilized in combination with the use of a multiple peptide synthesizer such as the "Advanced Chem Tech ACT-350." Using the above disclosure those skilled in the art can adapt such a multiple peptide synthesizer to synthesize hundreds, and even thousands of shaped peptides which cover a broad range of 3-dimensional structural configurations. After synthesizing large numbers of shaped peptides the shaped peptides can be screened for their affinity to a particular receptor such as their binding affinity to a particular antibody.

The cysteine-rich C-terminal domains of the *P. falciparum* merozoite surface protein 1 (MSP-1) induce

5 malaria neutralizing antibodies (see Majarian, W. R. et al., Journal of Immunology, volume 132, pages 3131-3137 (1984) which discloses passive protection against marine malaria using an IgG3 monoclonal antibody; also see

10 Blackman et al., Journal of Experimental Medicine, volume 172, pages 379-382 (1990) which discloses a single fragment of a malaria merozoite surface protein which remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies; and also

15 see Chang, S. P. et al., Journal of Immunology, volume 149, pages 548-555 (1992) which discloses a carboxyl-terminal fragment of plasmidum falciparum gp195 expressed by a recombinant baculovirus which induces antibodies that completely inhibit parasite growth).

20 Accordingly, the cysteine-rich C-terminal domain is the area of interest with respect to producing a vaccine. The above-cited publications by Majarian et al. and Chang et al. indicate that the antigenicity and immunogenicity of the C-terminal region is completely dependent on confirmation.

A pattern of twelve cysteines has been observed in the C-terminal domain of MSP-1 in several strains of malaria. This pattern is consistent with two tandem epidermal growth factor (EGF)-like domains. (See

25 Blackman et al., MOL. Biochem. PAR., volume 49, pages 29-34 (1991) which discloses the proteolytic process of the *plasmodium falciparum* merozoite surface protein-1 produces a membrane-fragment containing two epidermal growth factor-like domains). The EGF is representative

30 of a large and growing family of proteins which share structural homology with each other. Several EGF-like domains have been chemically synthesized and their solution structures determined by NMR. (See Kline et al., Biochemistry, volume 29, pages 7805-7813 which

35 relates to solution structures of human transforming

growth factor alpha derived from  $^1\text{H}$  NMR data). The 3-dimensional structures are similar and provide templates for the synthesis of constrained MSP-1 C-terminal peptides.

5           The most prominent, solvent exposed region of EGF-like proteins is the B-loop, a B-hairpin that has been reported to be an immunogenic. An important example of such a protein for malaria is Pfs25, which is a 25kD protein on the surface of *P. falciparum* ookinetes, which  
10           is composed of four tandem EGF-like domains (see Kaslow, D. C. et al., Nature, volume 333, pages 74-76 (1988) which discloses a vaccine candidate from the sexual stage of human malaria that contains EGF-like domains).

          Yeast recombinant Pfs25 elicits transmission  
15           blocking serum. Accordingly, such a protein can be used as a model for the production of a vaccine using the synthesis technology of the present invention. Several Mabs which block malaria transmission have been characterized (see Barr, P. J., et al., Journal of  
20           Experimental Medicine, volume 174, pages 1203-1208 (1991) which discloses recombinant Pfs25 protein of *P. falciparum* as eliciting malaria transmission-blocking immunity in experimental animals). One of the Mabs, 4B7 maps to the B-loop of the third EGF-like domain. The 4B7  
25           binds better to native protein than to either yeast recombinant Pfs or to peptide. Further, the 4B7 as well as other Mabs with respect to Pfs25 were used in order to develop a vaccine using the synthesis technology of the present invention. Specifically, we have used such  
30           peptides and antibodies and established that shaping a B-loop peptide makes it possible to obtain significant improvements in affinity to the antibodies.

          Although the protein Pfs25 may be of interest with respect to its ability to act as a vaccine, in  
35           accordance with the present invention it is used as a 3-

dimensional model for producing a shaped peptide. Such a shaped peptide can act as an effective multistage vaccine by blocking escape mutants more likely to form under immune pressure generated by a vaccine. The 3-

5 dimensionally stabilized peptides produced using the synthesis technology of the present invention have greater vaccine capability in that the linear Pfs25 peptides have not been shown to be capable of eliciting the desired transmission blocking activity.

10 In addition to producing 3-dimensionally stabilized Pfs25 similar work has been carried out with respect to MSP-1 with its two potential EGF-like domains. This work has led to the identification of a new  
15 conformational epitope on MSP-1 that can be mimicked by a constrained peptide produced in accordance with the synthesis technology of the present invention.


#### Example 49

FmocNHCH(CH<sub>2</sub>CH<sub>2</sub>CH(OCH<sub>3</sub>)<sub>2</sub>)COOH could be made by  
20 the synthesis outlined in Scheme 10 with references to similar syntheses.

25

30

35

Scheme 10

SUBSTITUTE SHEET



Such a reaction scheme can be employed for substituting a Class II mimic for the hydrogen bond which is often observed between the carboxyl group oxygen of the N-cap Asp or Asn side chains and the mainchain amide NHY proton of the N-cap + 3 amino acid. An argument (above) has been made for the existence of this structure in the HIV V3 loop. This link allows one to insert a hydrogen bond mimic into the middle of an amino acid sequence thus allowing one to covalently link different conformationally restricted structural units.

The procedure of Example 49 could be utilized for linking the "B-hairpin" region and the alpha helical region of the V3 loop into one structure. An ability to link two secondary structures could favor the formation of a supersecondary structure particularly in the context of a disulfide loop. This larger structure could reconstitute conformational epitopes and prove useful as an improved panning reagent or vaccine.

Since the introduction of hydrogen bond mimics on solid supports can be automated and in fact is in the process of being automated at this time, these larger structures are potentially accessible.

#### HELICIZED PEPTIDES

##### Example 50

[LeuAla]NucSiteALFQKEKMLGGCG-NH<sub>2</sub> was synthesized in the same manner as Example 49. It has been extensively characterized in 1D and 2D NMR experiments and found to form significant fraction of full length alpha helix in water.

Example 49 contains an epitope from Patarroyo's malaria vaccine (M.E. Patarroyo et al., (1988) Nature 332:158). This epitope is predicted to be alpha helical by GORBTURN.

[LeuAla]NucSite was found to increase the efficacy of this epitope in a monkey challenge trial with *P. falciparum* merozoites, the major form of human malaria. Challenge experiments were carried out.

5

#### Example 51

[LeuAla]NucSiteAEAAKAAAKRAQGY-NH<sub>2</sub> was synthesized on solid support using methods described above. This demonstrates that longer peptides can be  
10 helicized by inserting the Class II mimic into peptides on a solid support. It was identified by mass spectroscopy and the 1D NMR spectra of this peptide in water is consistent with the presence of substantial fraction of alpha helix.

15 The compound of Example 51 was synthesized as a potential mimic for the glucocorticoid receptor DNA-binding domain. NMR spectroscopy reveals the cognate sequence is helical in the protein (T. Hard et al., Science 249:157 (199)) and X-ray crystallography shows it  
20 binding specifically to the major groove (B.F. Luisi et al., Science 352:497 (1991)). The helix could be responsible for DNA recognition. Reagents that show specificity for DNA sequences are potential anticancer drugs.

25

#### Example 52

##### Mimicking a Neutralizing Epitope on Pfs25 with a Shaped Peptide

Antibodies were obtained which were Mab and  
30 more specifically 4B7 which completely blocks *P. falciparum* transmission to anopheles. ELISA assays are carried out to demonstrate the binding of different proteins to 4B7. By carrying out such assays it will be found that native Pfs25 demonstrates relatively good  
35 binding whereas poorer binding is obtained with







incorrectly folded yeast recombinant prot in and weak binding is obtain d through peptides corresponding to the putative B-loop of the third EGF-like domain. The Pfs25 peptide by itself is not capable of inducing protective antibodies. Using this information provided a well-defined system for testing the antigenicity and vaccine potential of a shaped peptide.

An examination of published NMR structures for several EGF-like proteins reveals similarity in the 3-dimensional structure particularly with respect to the B-loop region which adapts to a B-hairpin confirmation. Further examination of the B-loop, B-hairpin for EGF alpha (a prototypical EGF-like protein that can be accessed from the protein data base 4TGF) for display shows this loop is fully exposed to solvent on one side while its underside is partially buried or hindered as is shown within figure 5. The loops are characterized by distinct pattern of cysteine residues at the base of the loop which form three different cysteines with other parts of the molecule. This pattern is reflected within known EGF-like structures.

Using the methodology of the present invention the Pfs25 B-loop peptide was constrained to a hairpin using prototypical EGF structure as a guide. This was done by substituting predicted hydrogen bonds with a covalent mimic in a manner as outlined within figure 5.

A series of three loops of increasing size based on the predicted hydrogen bonding pattern were synthesized as shown within Table 4 below.

Table 4: Peptides and Hairpins

	1. Pfs Linear 1	Acetyl-GILDTSNPVKTGVGGG-NH <sub>2</sub>
5	2. Pfs Linear 2 (Cys)	Acetyl-GILDTSNPVKTGVGGC-NH <sub>2</sub>
	3. Pfs Loop 1	 JDTSNPVKTGZG-NH <sub>2</sub>
10	4. Big Pfs Loop 1 (Cys)	 JILDTSNPVKTGVGZC-NH <sub>2</sub>
	5. Big Pfs Loop 1	 JILDTSNPVKTGVGZG-NH <sub>2</sub>
15	6. Bigger Pfs Loop 1 (Cys)	 JK (Acm) ILDTSNPVKTGVC (Acm) SGZC-NH <sub>2</sub>
	7. Pfs Loop 2 (Cys)	 JILDTSNPVKTGZC-NH <sub>2</sub>
20	8. Pfs Loop 2	 JILDTSNPVKTGZG-NH <sub>2</sub>

The peptides of Table 4 place the SNPV at the apex of the hairpin and two cysteines opposite each other at the base of the loop. The positioning of Pro at the third position of the turn would require that the peptide adapt to a cis peptide bond commonly found in type VI turns.

At this point, it should be pointed out that computer analogs exist for predicting the secondary structure of peptides. One such analog is known as GORBTURN which analog provides a strong prediction for a non-specific reverse turn at TSNP but not at SNPV. The amino acids SNP are highly preferred amino acids for a type VIII turn which is the third most common turn found

in proteins (see Wilmot, C. M., et al., Prot. Eng., volume 3, pages 479-493 (1990)). The amino acid Pro occupies the (i + 3) amino acid of this turn. Such a configuration places the apex of the hairpin in a  
5 different tetrapeptide frame from that predicted from the prototypical EGF-like structure. These considerations provided the rationale for testing an alternative structure (loop 2, as shown in Table 4) and a means of  
10 assessing the effect that a change in the position of the hydrazone link could have on binding to the antibody 4B7.

Using the advanced chem tech ACT-350 multipeptide synthesizer, each of the loops shown within Table 4 were synthesized. In addition to the loops of Table 4 which come in pairs with either a cysteine C-  
15 terminal for use in ELISA or a Gly terminus for use in competition ELISA, linear peptides corresponding to the loops were also synthesized. A flow diagram showing the synthesis protocol is shown within figure 6.

Each peptide and loop was purified by a  
20 homogeneous peak by HPLC (<95% pure). Further, their mass was confirmed by FAB mass spectroscopy. Each loop was obtained in relatively high yields. The high yield obtained is an indication of an acceptable folding pattern for the loop. However, the loop 1 failed to  
25 close when Asp(But) was employed and required the use of ASP(Bzl) which was deprotected following cyclization. From this, it can be concluded that a free Asp adjacent to J competes with and prevents ring closure. The working set of purified peptides is listed in Table 4.

30

#### Example 53

##### Peptide-Antibody Binding Assays

Four different antibodies were used in ELISA assays which antibodies were 4B7, 1D2, 1D3 and 1C7. Each  
35 of the four antibodies is known to bind to native Pfs25

and also known not to bind to a Pfs25 reduced protein exhibiting complete conformational dependence. The cysteine-rich peptides described above were synthesized in the manner described above and then prepared for use in connection with an ELISA assay as an adsorbent by coupling each of these shaped peptides to the same batch of malemuted activated BSA (Pierce Chemical Company). The coupling was driven to completion with the same excess amounts of peptides and judged to be equivalent by a different assay which measures the remaining unconjugated peptide. Thereafter, each of the conjugates was adsorbed onto a Nunc microtiter well at varying concentrations in PBS. The ascites fluid and the partially purified IgG included approximately the same IgG concentration. Both preparations resulted in approximately the same titers. Adsorbent saturation of titer wells was achieved using 0.2  $\mu$ g BSA/100  $\mu$ l PBS. Titters were determined using standard procedures and the results are shown below in Table 5. The titer results shown are midpoints of the titration curve and are reproducible within a factor of about 2.

Table 5  
Titters of 4B7 Against Peptide and Loops

25	Linear	1,000
	Big Loop 1	256,000
	Bigger Loop 1	64,000
	Loop 2	512,000

30 As can be seen in Table 5 the titers against loops are substantially higher than against the linear peptide. The lowest titer for the loops is 64 times the titer for the linear peptide. When the same linear  
35 peptide and loops were tested against the other Mabs only

-100-

1D3 showed a titer against a conjugate (Big Loop 1:80) with a detectable reaction against the other peptides including loop 2. Accordingly, a nonspecific reaction with the loop can be ruled out. The hydrazone link is chemically stable over a broad range of pH. More specifically it is stable at neutral pH and physiological temperatures with no detectable change after three weeks. The loop-BSA conjugate shows no reaction with the secondary antibody. While 1D3 binds to Big Loop 1 it shows no sign of binding loop 2. However, 4B7 binds both loops tightly establishing specificity. In addition, a crystal structure of an unrelated Fab-loop complex shows no sign of a covalently bonded interaction with the binding site and crystals of Fab-loop conjugates have remained stable for months. These results allow one to conclude that the large increases in titers against loops are due to higher affinities of these 3-dimensionally stabilized structures to the antibodies they were tested against in the ELISA assay.

#### Example 54

##### Competition Assays

Competition ELISAs were run to determine the relative affinities of linear peptide and loops for 4B7. In these experiments, 0.1  $\mu$ g BigLoop1-BSA/100  $\mu$ l PBS were used as adsorbent. It is possible that the results will differ with different adsorbents. Instead of preincubating the antigen with Mab as is often the practice, the antigen was added to the titer wells adsorbed with conjugate before adding Mab to the mixture. This provides a measure of kinetic as well as thermodynamic competition which may be the more apt comparison. Competition curves were well behaved. Relative binding affinities are: Linear(1): Big Pfs Loop 1 (4-8) and Loop 2 (40-50). These results confirm that

both loops bind better than linear peptide to 4B7. The range of affinities, however, are smaller than that observed in the titer experiments described in Example 53 and shown in Table 2. This may reflect the use of too much antibody in the competition assay which must be reevaluated or bivalent binding to the adsorbed peptide-protein conjugate that can not be achieved in solution. Another possibility is that peptide covalently linked to BSA is more tightly adsorbed to the protein surface than the loop and less accessible to binding.

It is surprising to find that Loop 2 binds better than Big Loop 1 to 4B7 since it was designed on the basis of a "less reliable" prediction. It raises the possibility that Loop 2 more closely mirrors the native, neutralizing epitope and emphasizes the need to test alternative structures. For this reason, we sought to confirm this preference by screening other Mabs. 1D3 binds Loop 1 alone and not Loop 2 in ELISA. However, Loop 2 lacks two amino acids present in Loop 1 which could be critical for binding and other comparisons are warranted. It might be noted that 1D3 shows complete dependence on a native conformation of Pfs25 for binding and until these experiments, the 1D3 binding site on Pfs25 was unknown. The fact that 1D3 binds the B-loop peptide and like 4B7 completely blocks transmission confirms the third EGF-domain B-loop as a neutralizing epitope. (See Barr et al., J. Expt. Med., Vol. 174, pp. 1203-1208 (1991)).

30 Example 55  
Mimicking a Conformational Epitope

Procedures were carried out in order to mimic a conformational epitope on the EGF-like C-terminal domain of MSP-1. In order to carry out the experiments the antibody Mab 5B1 was obtained along with rabbit



polyclonal serum raised against MSP-1. It has been determined that 5B1 binds to the cysteine-rich C-terminal domain and partially neutralizes merozoite invasion of erythrocytes. Further, two additional Mabs, 12.8 and 12.10 have been identified which bind to this region and partially neutralize invasion (see Blackman et al., Journal of Experimental Medicine, volume 172, pages 379-382 (1990)). Further, it is known that passive transfer of a Mab to *P. yoelii* protects in vivo (see Majarian et al., Journal of Immunology, volume 132, pages 3131-3137 (1984)).

Each of these antibodies (Mabs) and polyclonal sera show complete dependence on intact cysteine residues for binding. The pattern of 12 cysteines in the C-terminal domain suggests two tandem EGF-like domains (see Blackman et al., Mol. Biochem. Par., volume 49, pages 29-34 (1991)). These EGF-like domains were referred to as EGF-1 (N-terminal) and EGF-2 (C-terminal). It has also been shown that 5B1, 12.8 and 12.10 as well as several other Mabs which have not demonstrated neutralizing activity, bind the recombinant EGF-1 domain. Further, it has been shown that polyclonal serum to recombinant BV-42 which includes the MSP-1 C-terminal domain completely neutralizes merozoites. Based thereon it is suggested that the neutralizing epitopes are in the cysteine-rich C-terminal domain (see Chang, et al., Journal of Immunology, volume 149, pages 548-555 (1992)). Presently, we do not believe any Mabs have been identified that bind the EGF-2 domain.

The rabbit polyclonal sera was raised against complete, intact MSP-1 purified from *P. falciparum* FCR3 blood stage merozoites. It blocks merozoite invasion. Binding of polyclonal serum to the MSP-1 cysteine-rich C-terminal domain is completely lost on reduction of the

cysteines, indicating that antibodies to this region are formed against conformational epitopes.

Based on the above described experiments relating to Pfs25, we reasoned that peptide loops based on the presumed EGF domains in MSP-1 might prove highly antigenic in ELISA. We therefore synthesized constrained B-loop peptides based on the predicted EGF-1 and EGF-2 domains. As with Pfs25 we modeled the EGF-1 and EGF-2 loops on the prototypical EGF structure (Figure 2). The two cysteines at the base of the loop were positioned opposite one another as with BigPfsLoop 1 letting the remainder of the loop fall at will.

Although others have reported that antibodies to MSP-1 do not react with the reduced C-terminal domains, it does not appear that anyone has screened these antibodies against overlapping peptides from this region. It is possible that highly concentrated adsorbed peptide can detect antibodies better than reduced, denatured protein. Therefore, in addition to the loops, we synthesized complete sets of overlapping 20-mers displaced every ten residues for EGF-1 and EGF-2 for both of the known *P. falciparum* allelic forms represented by the FC27 and K1 strains. Relevant linear peptides and cyclic B-loop peptides are listed in Table 3. All but the C-terminal cysteines are protected with acetamide groups (Acm) to prevent oligomerization. Whereas relatively good yields of the EGF-2 loops were obtained, the EGF-1 loop was obtained with difficulty. Masses of each of the peptides were confirmed by FAB mass spectroscopy.

Table 6: MSP-1 peptides and loops


## 1. Linear EGF-1, 20 mer

AcetylINSGC (Acm) FRHLDERBEC (Acm) KC (Acm) LLNC-NH<sub>2</sub>

## 2. Linear EGF-2, 20 mer

AcetylATC (Acm) TEEDSGSSRKKITC (Acm) EC (Acm) C-NH<sub>2</sub>

## 3. EGF-1 Loop (Cys)


 JFRHLDERBEGZC-NH<sub>2</sub> FC27 and K1 Strains

## 4. EGF-2 Loop 1 (Cys)


 JTEEDSGSSRKKITGZC-NH<sub>2</sub> FC27 Strain

## 5. Linear EGF-2

AcetylGTEEDSGSNGKKITGGG-NH<sub>2</sub> K1 Strain

## 6. EGF-2 Loop 2 (Cys)


 JTEEDSGSNRKKITGZC-NH<sub>2</sub> K1 Strain

## 7. EGF-2 Loop 2


 JTEEDSGSNGKKITGZG-NH<sub>2</sub>, K1 Strain

Each of the C-terminal Cys peptides were linked to maleimide-activated BSA for use as adsorbents in ELISA. The polyclonal serum shows an IFA against FCR3 merozoites of approximately 50. Titer data for the polyclonal sera against the peptides and loops is summarized in Table 7. None of the peptides or loops bound 1B5. No reaction of the polyclonal antibodies was observed with the linear peptide conjugates, confirming the results of others who have observed that anti MSP-1 serum does not bind the C-terminal domains. No reaction was observed with the EGF-1 Loop. A titer (midpoint of

titration curve) was observed against both EGF-2 loops. These loops differ by two amino acids among thirteen for the epitope.

5

Table 7

Titers of polyclonal MSP-1 serum against peptides and loops

10	1. Overlapping 20 mers: <20
	2. EGF-1 Loop: <20
	3. EGF-2 Loop 1, FC27 strain: 200
	4. EGF-2 Loop 2, K1 strain: 200

Competitive ELISA experiments were carried out to confirm the identification of the epitope. The EGF-2 Loop 2 peptide (No. 6, Table 6) BSA conjugate was used as adsorbent. The three competitive solution phase peptides were a linear peptide control (Pfs Linear 1, Table 4), the linear EGF-2, K1 strain (No. 5, Table 6) and the corresponding EGF-2 Loop 2 (No. 7, Table 6). While the control peptide showed no sign of competition at even high concentrations, both linear EGF-2 and EGF-2 Loop 2 show similar abilities to compete. Loop 2 is slightly more effective since it alone completely blocks binding to the adsorbent at high concentration. The results show a narrower range in binding affinities than in titers (> 10 fold). Accordingly, conditions for this experiment should be examined more carefully. Regardless, both the titer and competition experiments lead us to conclude that a new conformational epitope on the C-terminal domain of MSP-1 has been identified. Although Mabs have been detected against the EGF-1 domain, none have been found which bind to the EGF-2 domain. Evidence for polyclonal antibodies to the EGF-2 domain B-loop indicates that it is highly exposed. In addition, this

35

-106-

reaction provides supporting evidence that the EGF-2 domain is indeed EGF-like.

Improvements in binding affinity to antibodies formed against native epitopes indicate that the loops more closely mimic the native conformation than the peptides. However, the EGF-2 loop peptides as constituted may not be perfect mimics. Our initial competition ELISA shows that affinity for the EGF-2 Loop 2 is not that much greater than that for the linear peptide. It is possible that the hydrogen bond mimic could be positioned elsewhere to greater effect. The results with the different Pfs25 loops indicate that up to a 45-fold improvement in affinity can be achieved. The smaller Pfs loop 2 binds more tightly than Big Pfs Loop 1. Thus the higher affinity arises from a repositioning of the hydrogen bond mimic and not from an addition of or change in amino acids. Accordingly, more tightly binding EGF-2 loops might also be formed by repositioning the hydrogen bond mimic and juxtaposing different sets of amino acids. This strategy could also lead to an EGF-1 loop that might bind polyclonal antibodies.

#### Results - Malaria Vaccines

The 3-dimensionally stabilized shaped peptides produced in accordance with the present invention have been shown to demonstrate enormous improvement in titer of antibodies as compared with linear peptides. These results are believed to be due to the comparative 3-dimensional shape i.e. linear peptides are essentially small bits of denatured protein whereas the stabilized shaped peptides of the present invention have stabilized 3-dimensional configurations. While anti-MSP-1 rabbit polyclonal serum shows no reaction with linear EGF-2, it binds the corresponding shaped peptide under the same

conditions. These results mirror those observed in immunoblots where polyclonal sera and Mabs to the cysteine-rich C-terminal MSP-1 domains exhibit total dependence on a conformation. These observations have  
5 now been reproduced using shaped peptides of the present invention which allow the precise identification of the epitope if not its conformation. In order to further expand on the results utilizing peptide libraries on phage or pins is suggested which may allow identification  
10 of conformational epitopes. However, it is pointed out that such methods may prove problematic due to weak interactions of flexible peptides with receptors.

To further develop an effective multistage vaccine which could be used with respect to malaria it is  
15 important to assess the immunogenicity of the shaped malaria peptides produced in accordance with applicants invention. The Big Pfs 25 Loop 1 binds better than linear peptide to the antibodies Mabs, 4B7 and 1D3. Both of these antibodies completely block transmission of  
20 *P. falciparum* to Anopheles. This demonstrates that the Loop 1 shaped peptide more closely mimics the neutralizing epitope. Attempts to elicit transmission blocking with peptide vaccines have not worked presumably due to a conformational requirement. Since the B-loop of  
25 EGF-like proteins is well exposed such should provide an effective component of a multistage vaccine. Such a vaccine can be created by combining one or more of the shaped peptides described above in a pharmaceutically acceptable carrier. Such a vaccine would be administered  
30 by injection in amounts determined by the caregiver to generate a sufficient antibody response so as to render the patient immune from infection with malaria.

The instant invention is shown and described herein in what is considered to be the most practical,  
35 and preferred embodiments. It is recognized, however,

that departures may be made therefrom which are within the scope of the invention and that obvious modifications will occur to one skilled in the art upon reading this disclosure.

5

10

15

20

25



30

35

WHAT IS CLAIMED:

1. A biologically active peptide comprising a three-dimensionally stabilized configuration which substantially mimics the three-dimensional configuration of an active site of a natural biologically active protein, the three-dimensional configuration of the peptide being stabilized by a covalently bound linking group which covalently binds non-adjointing amino acids in the peptide.


2. The peptide as claimed in claim 1, wherein the non-adjointing amino acids are covalently bound by a linking group to form a structure represented by a general structural formula selected from the group consisting of:



wherein R is hydrogen or an alkyl containing 1-6 carbon atoms; and



-110-



10 wherein  $\text{R}^1$ ,  $\text{R}^2$ , and  $\text{R}^3$  are each, independently, hydrogen or an alkyl moiety containing 1 to 6 carbon atoms,  $\text{R}^4$  is any atom or molecular group of atoms with the required electron configuration,  $m$  is an integer of from 0 to 5,  $\text{aa}$  is an amino acid moiety, and  $n$  is an integer of from 1 to 2,000.

15 3. The peptide as claimed in claim 2, wherein  $n$  is an integer of from 3 to 30.

20 4. The peptide as claimed in claim 1, wherein the peptide has a formula selected from the group consisting of:



-111-

[ ]  
JILDTSNPVKTGZC-NH<sub>2</sub> ;

5 [ ]  
JILDTSNPVKTGZG-NH<sub>2</sub> ;


10 [ ]  
JFRHLDEREEGZC-NH<sub>2</sub> ;

[ ]  
JTEEDSGSSRKKITGZC-NH<sub>2</sub> ;


15 [ ]  
JTEEDSGSNRKKITGZC-NH<sub>2</sub> ; and

20 [ ]  
JTEEDSGSNGKKITGZG-NH<sub>2</sub> .


25 5. The peptide as claimed in claim 4, wherein  
the non-adjoining amino acids are covalently bound by a  
linking group to form a structure represented by a  
general structural formula selected from the group  
consisting of:



-112-



wherein R is hydrogen or an alkyl containing 1-6 carbon atoms; and



wherein  $\text{R}^1$ ,  $\text{R}^2$ , and  $\text{R}^3$  are each, independently, hydrogen or an alkyl moiety containing 1 to 6 carbon atoms,  $\text{R}^4$  is any atom or molecular group of atoms with the required electron configuration, m is an integer of from 0 to 5, aa is an amino acid moiety, and n is an integer of from 1 to 2,000.

25 6. The peptide as claimed in claim 5, wherein n is an integer of from 3 to 30.

30 7. A method of synthesizing a three-dimensionally stabilized peptide which mimics the three-dimensional configuration of a portion of a natural, biologically active protein, comprising:

determining the amino acid sequence and the three-dimensional configuration of an active site of a biologically active protein;

35

-113-

identifying a stabilizing hydrogen bond between amino acids which bond stabilizes the three-dimensional structure of the active site;

5 synthesizing a peptide having substantially the same amino acid sequence as the active site of the biologically active polypeptide;

10 forming a covalent bond between amino acids of the peptide by introducing a bridging group between the amino acids to thereby provide a three-dimensionally stabilized peptide; and

isolating the three-dimensionally stabilized peptide.

15 8. The method as claimed in claim 7, wherein the bridging group is selected from the group consisting of  $-(N)-C(CH_3)-N(H^+)-CH_2-(N)-$ ;  $-(N)-C(CH_3)-N(H^+)-CH_2-CH_2-(N)-$ ; and  $-(N)-N=CH-CH_2-CH_2-CH_2-(C)-$  wherein the atoms in parentheses denote atoms corresponding to amide and carbonyl peptide backbone atoms of the peptide.

20

9. The method as claimed in claim 8, wherein the bridging group is introduced by reacting amino acids of the peptide with a bridging divalent radical which forms the bridging group.

25

10. The method as claimed in claim 9, wherein the bridging divalent radical is reacted with amino acids which correspond to the amino acids which form the stabilizing hydrogen bond of the active site of the polypeptide.

30

11. The method as claimed in claim 7, wherein the active site is on a sterically accessible region of the protein.

35

12. The method as claimed in claim 11, wherein the sterically accessible region includes a configuration selected from the group consisting of a reverse turn, an  $\beta$ -helix, a loop, a  $\beta$ -hairpin, and a  $\beta$ -sheet.

5

13. The method as claimed in claim 7, wherein at least two stabilizing hydrogen bonds exist between two pairs of amino acids in the protein and wherein each of the pairs of amino acids in the synthesized peptide  
10 corresponding to the pairs of amino acids between which stabilizing hydrogen bonds exist is modified so that the pairs of amino acids are covalently bound by a bridging group.

15

14. The method as claimed in claim 7, wherein a plurality of stabilizing hydrogen bonds exist between pairs of amino acids in the protein and wherein a plurality of the pairs of amino acids in the synthesized peptide corresponding to the pairs of amino acids between  
20 which stabilizing hydrogen bonds exist are modified so that the amino acids are covalently bound to a bridging group.

25

15. A three-dimensionally stabilized peptide prepared by the method of claim 7.

30

16. A three-dimensionally stabilized peptide which mimics a three-dimensional configuration of a portion of a natural biologically active protein, wherein a H-bond represented by  $(C)=O \cdots H-(N)$  is stabilized by a covalently bound bridging group selected from the group consisting of  $-(N)-C(CH_3)=N(H^+)-CH_2-(N)-$ ;  $-(N)-C(CH_3)=N(H^+)-CH_2-CH_2-(N)-$ ; and  $-(N)-N=CH-CH_2-CH_2-CH_2-(C)-$  wherein the atoms in parentheses denote atoms

35


corresponding to amide and carbonyl peptide backbone atoms of the natural biologically active protein.

17. The peptide of claim 16, wherein the three-dimensional configuration is selected from the group consisting of a reverse turn, an  $\alpha$ -helix, a loop, a  $\beta$ -hairpin, and a  $\beta$ -sheet.

18. A three-dimensionally stabilized peptide containing from 3 to 2,000 amino acids, the peptide having a stabilizing hydrogen bond, represented by a normal structure, stabilized by a covalent bond, represented by a Class 1 or Class 2 structure, wherein the normal Class 1 and Class 2 structures are as follows:

15

20



Normal

class 1

class 2

wherein R is H or an alkyl moiety containing 1 to 6 carbons, or an acid represented by  $-(\text{CH}_2)_n-\text{CO}_2\text{H}$  where n is an integer of from 1 to 6.

19. A biologically active compound comprising amino acids linked in a chain to form a peptide, the peptide having a position which is three-dimensionally stabilized by a bridging group selected from the group consisting of  $-(\text{N})-\text{C}(\text{CH}_3)=\text{N}(\text{H}^+)-\text{CH}_2-(\text{N})-$ ;  $-(\text{N})-\text{C}(\text{CH}_3)=\text{N}(\text{H}^+)-\text{CH}_2-\text{CH}_2-(\text{N})-$ ; and  $-(\text{N})-\text{N}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-(\text{C})-$  wherein the atoms in parentheses denote atoms

35

-116-

corresponding to amide and carbonyl peptide backbone atoms of the peptide.

20. A biologically active peptide, comprising  
5 a three-dimensionally stabilized configuration which substantially mimics the three-dimensional configuration of an active site of a natural biologically active protein, wherein the active site of the natural  
10 biologically active protein includes amino acids which are held in their three-dimensional configuration by at least one hydrogen bond of the formula  $(C)=O \cdots H-(N)$ , the three-dimensional configuration of the peptide including identical or substantially identical amino acids to the  
15 amino acids present at the active site of the naturally occurring biologically active protein, wherein the hydrogen bond is replaced by a bridging covalent bond selected from the group consisting of  $-(N)-CR-NH+- (C)-$  and  $-(N)-N=CH- (C)-$  wherein the atoms in parentheses denote atoms corresponding to the amide and carbonyl  
20 peptide backbone atoms of the peptide.


21. The peptide as claimed in claim 20,  
wherein the peptide forms a ring containing 7 to 6,000  
25 amino acids.

22. The peptide as claimed in claim 21,  
wherein the ring contains from 10 to 20 amino acids.

30


35

23. The peptide as claimed in claim 20,  
wherein the peptide has the following general structural  
formula:



wherein (aa) is an amino acid, n is an integer of from 1  
to 2,000,  $R^4$  is any atom or molecular group of atoms with  
the required electron configuration, m is an integer of  
from 0 to 6,  $R^1$  and  $R^2$  are each independently hydrogen or  
an alkyl moiety containing 1 to 6 carbon atoms, and  $R^3$  is  
hydrogen, an alkyl containing 1 to 6 carbon atoms, or a  
chain of amino acids containing 1 to 2,000 amino acids.

24. The peptide as claimed in claim 20,  
wherein the peptide has the following general structural  
formula:



wherein  $R^5$  is an alkoxy containing 1 to 6 carbon atoms,  
phenoxy, naphthyloxy, benzoxy,  $-NH_2$  or an amino acid  
sequence containing 1 to 2,000 amino acids, (aa) is an  
amino acid, n is an integer of from 1 to 2,000, X is  
optionally present and if present is selected from the  
group consisting of  $-CH_2-$ ,  $-NH-$ ,  $-CH-$ , and  $-NH$  with  
double bonds to CHR,  $R^6$  is optionally present and if



present is selected from the group consisting of hydrogen, an alkyl moiety containing 1 to 6 carbons atoms, an alkyl amine  $(CH_2)_n-NH_2$  wherein n is an integer of from 1 to 6 optionally connected to an amino acid chain containing 1 to 2,000 amino acids.

25. The peptide of claim 24 wherein  $(aa)_n$  is ile-glu-ser-leu-aspartic-ser-tyr, m is 2 and  $R^4$  is  $NH_2$ .

26. The compound of claim 24 wherein  $(aa)_n$  is leu-ala, m is 2 and  $R^4$  is Et.

27. A three-dimensionally stabilized peptide which mimics a three-dimensional configuration of a portion of a natural biologically active polypeptide, wherein the H-bond represented by  $(C)=O \cdots H-(N)$  is replaced by  $(C)-C-N-(N)$ .

28. A three-dimensionally stabilized peptide which mimics the three-dimensional configuration of a portion of a natural, biologically active polypeptide, produced by the process comprising the steps of:

noting the three-dimensional configuration of a known active site of a biologically active polypeptide and noting the amino acid sequence as well as hydrogen bonds existing between amino acids;

identifying a stabilizing hydrogen bond between amino acids in the active site of the polypeptide;

synthesizing a peptide having the same amino acid sequence as the active site of the biologically active polypeptide; and

replacing the stabilizing hydrogen bond with a spatially equivalent covalent linkage which mimics the stabilizing hydrogen bond, the replacing being carried out by reacting a first activated modified glycine at a


first position of the polypeptide with a second activated modified glycin at a second position on the polypeptide to obtain a linking group, the linking group being in the form of a divalent radical selected from the group

5 consisting of

- (N) -CH<sub>2</sub>-NH- (C) - ,
- (N) -CH<sub>2</sub>CH<sub>2</sub>-NH- (C) - , and
- (N) -N=CH- (C) - ; and

10 isolating the three-dimensionally stabilized peptide.

29. An assay device, comprising:  
a support surface; and  
a three-dimensionally stabilized peptide  
15 containing from 3 to 2,000 amino acids bound to the support surface, the peptide having a stabilizing hydrogen bond, represented by a normal structure, stabilized by a covalent bond, represented by a Class 1 or Class 2 structure, wherein the normal Class 1 and  
20 Class 2 structures are as follows:



30 wherein R is H or an alkyl moiety containing 1 to 6 carbons, or an acid represented by -(CH<sub>2</sub>)<sub>n</sub>-CO<sub>2</sub>H where n is an integer of from 1 to 6.

35 30. A method of generating an antibody in a living being with an immune system, comprising:

-120-

administ ring to the living being a  
biologically active compound comprising amino acids  
linked in a chain to form a peptide, the peptide having a  
position which is three-dimensionally stabilized by a  
5 bridging group selected from the group consisting of  
- (N) - C(CH<sub>3</sub>) = N(H<sup>+</sup>) - CH<sub>2</sub> - (N) - ; - (N) - C(CH<sub>3</sub>) = N(H<sup>+</sup>) - CH<sub>2</sub> - CH<sub>2</sub> -  
(N) - ; and - (N) - N = CH - CH<sub>2</sub> - CH<sub>2</sub> - CH<sub>2</sub> - (C) - wherein the atoms in  
parentheses denote atoms corresponding to amide and  
carbonyl peptide backbone atoms of the peptide;  
10 allowing sufficient time for the immune system  
of the living being to generate antibodies to the  
biologically active compound;  
extracting sera from the living being; and  
isolating antibodies from the sera.

15

31. The method of claim 30, further  
comprising:

contacting the isolated antibodies with the  
biologically active compound and thereby recovering  
20 antibodies specific to the biologically active compound.

32. The method of claim 31, comprising:  
cloning the antibodies specific to the  
biologically active compound to produce antibody clones;  
25 genetically mutating the antibody clones to  
obtain a library of mutated cloned antibodies;  
contacting the mutated cloned antibodies with  
the biologically active compound; and  
extracting mutated cloned antibodies with the  
30 highest binding affinity to the biologically active  
compound.

35

-121-

33. A method of treatment, comprising:  
administering to a living being a  
pharmaceutically effective amount of a mutated cloned  
antibody extracted as in claim 32.

5

34. A method of treatment, comprising:  
administering to a living being a  
pharmaceutically effective amount of the biologically  
active peptide of claim 1.

10

15


20

25


30

35


1/6




REVERSE TURN




$\alpha$ -HELIX



LOOP






$\beta$ -HAIRPIN



$\beta$ -SHEET

FIG. 1


2/6



SUBSTITUTE SHEET

FIG. 2

3/6







Predicted Regions of Secondary Structure in V3 Loop.  
 Arrows show direction of hydrogen bond;  $\text{NH} \rightarrow \text{O} = \text{CNH}$ .  
 ① → ② is for a side chain to main chain H-bond.

FIG. 3

SUBSTITUTE SHEET

4/6

[Leu Ala] Nuc Site ARQAHCAcmNISRAK - Cys - NH<sub>2</sub>

HIV(6)

FIG. 4

SUBSTITUTE SHEET



5/6





FIG. 5

SUBSTITUTE SHEET

6/6



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/03032

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : Please See Extra Sheet.

US CL : 530/317, 323, 345; 514/9; 424/85.8, 88; 435/7.1, 172.3

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/317, 323, 345; 514/9; 424/85.8, 88; 435/7.1, 172.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, APS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,642,334 ( Moore et al. ) 10 February 1987, col. 2, lines 18-23.	30-33
Y	US, A, 4,777,127 ( Suni et al. ) 11 October 1988, col. 7, lines 14-23.	30-33
X Y	UCLA Symp. Mol. Cell. Biol., New Ser., Volume 69, issued 10 September 1987, T. Arrhenius et al., " The Chemical Synthesis of Structured Peptides Using Covalent Hydrogen-Bond Mimics ", Pages 453-465, see entire document.	1-2, 7-12, 15-17, 19-20, 27 3-6, 13-14, 18, 21-26, 28-34



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be part of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 MAY 1993

Date of mailing of the international search report

16 JUN 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

CHRISTINA CHAN

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/03032

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	Vaccine, Volume 6, issued April 1988, A. C. Satterthwait et al., "Conformational Restriction of Peptidyl Immunogens with Covalent Replacement for the Hydrogen Bond", pages 99-103, see entire document.	1-2, 7-12, 15-17, <u>19-20, 27</u> 3-6, 13-14, 18, 21-26, 28-34
X Y	Revier et al EDS., "Peptides", published 1990, by ESCOM Science, (The Netherlands ) pages 870-872, see entire document.	1-2, 7-12, <u>15-17, 19-20, 27</u> 3-6, 13-14, 18, 21-26, 28-34
X Y	Grialt et al, EDS., "Peptides", published 1990, by ESCOM Science, (The Netherlands ) , pages 465-467, see entire document.	1-2, 7-12, <u>15-17, 19-20, 27</u> 3-6, 13-14, 18, 21-26, 28-34
Y	Fudenberg et al EDS., "Basic and Clinical Immunology" published 1976 by LANGE Medical Publications, (Los Altos, California ), pages 32-40, see page 33 in particular.	30-33

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/03032

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
(Telephone Practice)  
Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark n Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/03032

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C07K 1/00, 7/54, 15/00; A61K 37/02, 39/00, 39/395; C12N 15/00; G01N 33/53

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

I. Claims 1-29 and 34, drawn to a peptide, a method of making a peptide and a method of using a peptide, classified in Classes 530 and 514, Subclasses 323 and 9, respectively.

II. Claims 30-33, drawn to a method of making an antibody and a method of using an antibody, classified in Classes 435 and 424, Subclasses 172.3 and 85.8, respectively.

The inventions as grouped are distinct, each from the other, because they represent different inventive endeavors. The peptide, the method of making the peptide and the method of using the peptide in Group I would not suggest the method of making the antibody and the method of using the antibody in Group II.